

SECOND EDITION

# Health Professional's Guide *to* Gastrointestinal Nutrition

*EDITORS:*

Laura E. Matarese, PhD, RDN, LDN, FADA, FASPEN, FAND

Gerard E. Mullin, MD, AGAF, FACG, FACN

Kelly A. Tappenden, PhD, RDN, FASPEN

Academy of Nutrition and Dietetics  
120 S. Riverside Plaza, Suite 2190  
Chicago, IL 60606

*Health Professional's Guide to Gastrointestinal Nutrition*, Second Edition

ISBN 978-0-88091-216-7 (print)  
ISBN 978-0-88091-217-4 (eBook)  
Catalog Number 450523 (print)  
Catalog Number 450523e (eBook)

Copyright © 2023, Academy of Nutrition and Dietetics. All rights reserved. Except for brief quotations embodied in critical articles or reviews, no part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written consent of the publisher.

The views expressed in this publication are those of the authors and do not necessarily reflect policies and/or official positions of the Academy of Nutrition and Dietetics. Mention of product names in this publication does not constitute endorsement by the authors or the Academy of Nutrition and Dietetics. The Academy of Nutrition and Dietetics disclaims responsibility for the application of the information contained herein.

10 9 8 7 6 5 4 3 2 1

For more information on the Academy of Nutrition and Dietetics, visit  
[www.eatright.org](http://www.eatright.org).

---

#### **Library of Congress Cataloging-in-Publication Data**

Library of Congress Cataloging-in-Publication Data

Names: Matarese, Laura E., editor. | Mullin, Gerard E., editor. |

Tappenden, Kelly A., editor.

Title: Health professional's guide to gastrointestinal nutrition / Laura E.

Matarese, PhD, RDN, LDN, FADA, FASPEN, FAND, Gerard E. Mullin, MD, AGAF, FACG, Kelly A. Tappenden, PhD, RDN, FASPEN.

Description: Second edition. | Chicago, IL : Academy of Nutrition and Dietetics, [2022] | Includes bibliographical references and index.

Identifiers: LCCN 2022038257 (print) | LCCN 2022038258 (ebook) | ISBN 9780880912167 (print) | ISBN 9780880912174 (eBook)

Subjects: LCSH: Gastrointestinal system--Diseases--Nutritional aspects.

Classification: LCC RC802 .H43 2022 (print) | LCC RC802 (ebook) | DDC 616.3/30654--dc23/eng/20220829

LC record available at <https://lccn.loc.gov/2022038257>

LC ebook record available at <https://lccn.loc.gov/2022038258>

# Contents

List of Boxes, Tables, and Figures .....	v
Frequently Used Terms and Abbreviations.....	viii
Contributors .....	x
Reviewers .....	xiii
Foreword .....	xv
Preface .....	xvi
Acknowledgments.....	xviii
About the Editors .....	xix

## SECTION 1

### **Gastrointestinal Nutrition Assessment and Diagnostics**

<b>CHAPTER 1</b>	Nutrition Assessment for Patients With Gastrointestinal Disorders .....	2
<b>CHAPTER 2</b>	Gastrointestinal Tests and Procedures .....	27

## SECTION 2

### **Nutrition and Gastrointestinal-Related Disorders**

<b>CHAPTER 3</b>	Inflammatory Bowel Disease .....	42
<b>CHAPTER 4</b>	Short Bowel Syndrome .....	59
<b>CHAPTER 5</b>	Irritable Bowel Syndrome .....	74
<b>CHAPTER 6</b>	Celiac Disease .....	91
<b>CHAPTER 7</b>	Liver Disease .....	109
<b>CHAPTER 8</b>	Pancreatic Disease .....	126
<b>CHAPTER 9</b>	Pediatric-Originating Gastrointestinal Disorders .....	135
<b>CHAPTER 10</b>	Gastrointestinal Oncology .....	148

## SECTION 3

### **Nutrition and Gastrointestinal-Related Systemic Disorders**

CHAPTER 11	Medical Treatment of Obesity .....	174
CHAPTER 12	Eating Disorders .....	185
CHAPTER 13	Food Allergies and Intolerances.....	207

## SECTION 4

### **Overview of the Intestinal Microbiome**

CHAPTER 14	Intestinal Microbiome .....	224
CHAPTER 15	Prebiotics .....	254
CHAPTER 16	Probiotics .....	265

## SECTION 5

### **Surgical and Therapeutic Interventions for Gastrointestinal Disorders**

CHAPTER 17	Gastrointestinal Tract Surgery .....	284
CHAPTER 18	Bariatric Surgery .....	305
CHAPTER 19	Enteral Nutrition .....	333
CHAPTER 20	Parenteral Nutrition .....	364
CHAPTER 21	Pediatric Enteral and Parenteral Nutrition.....	376
CHAPTER 22	Home Parenteral and Enteral Nutrition .....	402
CHAPTER 23	Drug-Nutrient Interactions With Gastrointestinal Drugs .....	424
CHAPTER 24	Nutraceutical Supplements .....	436
CHAPTER 25	Ethical and Legal Considerations in Gastrointestinal Nutrition Interventions .....	455
	Continuing Professional Education .....	477
	Index.....	478

# Preface

THE GASTROINTESTINAL (GI) SYSTEM IS OFTEN UNDERAPPRECIATED DESPITE ITS VAST COMPLEXITY, which includes the mouth, pharynx, esophagus, stomach, biliary system, pancreas, liver, small intestine, large intestine, rectum, and anus. Functionally, the GI system is essential for the digestion and absorption of nutrients that sustain us, the immunity that protects us, and the metabolism that fuels us. Further, the GI system orchestrates function among distant organs and communicates with our central nervous system. An additional ecosystem is now known to exist within the GI system that provides and impacts many physiological processes. Despite all these critical, ongoing actions, we often take the GI system for granted until there is a problem.

With the success of the first edition of the *Health Professional's Guide to Gastrointestinal Nutrition*, we were asked to lead the development of a second edition. The book's purpose is to help registered dietitian nutritionists (RDNs) and other health care providers understand both the complexities of the GI system and the changes that occur in various disease states, with the goal of providing the best nutrition care for their patients. As a practice-oriented guide, this book is intended to help RDNs, physicians, interns, and students identify and alleviate or resolve the nutritional problems related to the GI tract that affect the health and quality of life of our patients.

For ease of use, the book is divided into five sections. **Section 1: Gastrointestinal Nutrition Assessment and Diagnostics** begins with a comprehensive chapter on nutrition assessment of the patient with GI disorders, which is the first step in the Nutrition Care Process. These patients frequently experience nutrition-related problems, including nutrient deficiencies due to the inability to digest and absorb nutrients. An overview of tests and procedures commonly performed for patients with GI disorders is provided in a separate chapter to identify the indications, preparation, and risks involved in diagnosing various disease states.

**Section 2: Nutrition and Gastrointestinal-Related Disorders** includes 10 chapters that examine specific GI tract diseases. There is a wealth of information on disease etiologies, symptoms, diagnostic techniques, and nutritional implications. These chapters also offer practical suggestions about selecting nutrition interventions that are appropriate for specific patients. The specific topics in this section include inflammatory bowel disease (Chapter 3), short bowel syndrome (Chapter 4), irritable bowel syndrome (Chapter 5), celiac disease (Chapter 6), liver disease (Chapter 7), pancreatic disease (Chapter 8), pediatric-originating gastrointestinal disorders (Chapter 9), and gastrointestinal oncology (Chapter 10).

**Section 3: Nutrition and Gastrointestinal Related Systemic Disorders** focuses on nutrition intervention for common systemic conditions with gastrointestinal implications. This section covers medical treatment of obesity (Chapter 11), eating disorders (Chapter 12), and food allergies and intolerances (Chapter 13).

With the emergence of evidence on the critical role of the gut microbiome in health and disease, a new **Section 4: Overview of the Intestinal Microbiome** addresses this area of critical knowledge for health care professionals. Physiological functions of the intestinal microbiome, diagnoses related to altered microbial communities, and nutritional strategies for optimizing the microbial community are included in chapters on the intestinal microbiome (Chapter 16), prebiotics (Chapter 17), and probiotics (Chapter 18).

**Section 5: Surgical and Therapeutic Interventions for Gastrointestinal Disorders** includes ten chapters. Chapters 17 and 18 focus on GI surgeries (bariatric and other GI surgeries), which explore how surgical interventions are used to address serious health

problems and how these might alter digestion and absorption. Chapters 19 to 22 focus on nutrition support, including the uses of enteral and parenteral nutrition in adult and pediatric patients, as well as the special challenges of administering nutrition support in the home care setting. The information in these chapters complements and expands upon the coverage of nutrition support interventions for specific GI disorders found in many of the earlier chapters of this book. Chapter 23 is a guide to drug-nutrient interactions that may occur with the medications used to treat GI disorders. Chapter 24 address the use of nutraceutical supplements. Although further rigorous, scientific investigation of the use of nutraceuticals is needed, this chapter can help readers separate the more promising options from those that have not demonstrated efficacy. Chapter 25 frames the ethical and legal issues that health care professionals may face when providing GI nutrition interventions, particularly when a patient or authorized caregiver chooses to refuse artificial nutrition and hydration.

There are many ways to use this book. You may wish to start at the beginning and read from cover to cover. Alternatively, we encourage you to turn to the chapters that are most relevant to the types of care you provide or begin with the topics that are least familiar to you. Whatever your strategy, our goal is that you find this *Health Professional's Guide to Gastrointestinal Nutrition* to be an essential evidence-based professional resource in your clinical practice.

Laura E. Matarese, PhD, RDN, LDN, FADA, FASPEN, FAND  
Gerard E. Mullin, MD, AGAF, FACG, FACN  
Kelly A. Tappenden, PhD, RDN, FASPEN

SAMPA E  
Not for Print  
or Sale

# Nutrition Assessment for Patients With Gastrointestinal Disorders

Kris M. Mogensen, MS, RD-AP, LDN, CNSC

## KEY POINTS

- Disorders of the gastrointestinal system can have a significant adverse impact on nutritional status by impairing ingestion, digestion, and absorption of food and nutrients, increasing nutritional losses and nutrient requirements, and ultimately influencing morbidity and mortality.
- The nutrition assessment is a comprehensive evaluation of the nutritional status of an individual. Nutrition screening occurs before the comprehensive nutrition assessment to identify patients who are malnourished or at risk for developing malnutrition.
- A complete nutrition assessment includes evaluating dietary data, biochemical test and procedure results; anthropometric measures; nutrition focused physical findings; and a personal, medical, and social history with the ultimate goal of improving clinical outcomes in patients with gastrointestinal disorders.

## Introduction

Disorders of the gastrointestinal (GI) system can have an adverse impact on nutritional status by impairing ingestion, digestion, and absorption of food and nutrients and increasing nutritional losses and nutrient requirements.<sup>1</sup> Nutritional status has a profound influence on morbidity and mortality from illness in the acute care setting in both patients who are non-critically ill and critically ill.<sup>2-6</sup> In the clinical setting, nutrition assessment is a comprehensive evaluation of the nutritional status of an individual patient. Nutrition screening occurs before the comprehensive nutrition assessment to help identify patients who are malnourished or at risk for developing malnutrition to assure timely and appropriate nutrition assessment.<sup>7</sup> Once a patient is identified as at risk, the patient should then undergo nutrition assessment.

As the first step of the Nutrition Care Process, nutrition assessment is defined as “a systematic method for obtaining, verifying, and interpreting data needed to identify nutrition-related problems, their causes, and significance.”<sup>8</sup> Nutrition assessment involves an initial evaluation of the patient, and ongoing monitoring and periodic reassessment is important to refine the individualized nutrition care plan to help maintain or improve the assessed status. The types of data collected during the assessment vary on a case-by-case basis but are organized into five general categories (see Box 1.1).<sup>8</sup> No single method is ideal for nutrition assessment; the use of a combination of methods is needed to effectively characterize nutritional status. All nutrition assessment methods provide indirect estimates of the process measured. Thus, the data obtained are usually compared to reference data to determine indicators of nutritional status.

## **BOX 1.1**

### Components of a Nutrition Assessment<sup>8</sup>

#### **Food/nutrition-related history**

Food and nutrient intake

Medication and dietary supplement intake, including herbs and other botanicals

Knowledge, beliefs, and attitudes

Food availability

Physical activity

Nutrition-related quality of life

#### **Biochemical data, medical tests, and procedures**

Laboratory data (eg, electrolytes, glucose, renal, liver, gastrointestinal profiles)

Tests (eg, gastric emptying time, resting metabolic rate)

#### **Anthropometric measurements**

Height

Weight

Body mass index

Weight history

Weight change

#### **Nutrition focused physical findings**

Physical appearance

Skin, hair, and nail assessment

Muscle and fat wasting

Edema assessment

Swallow function

Abdominal exam

Evaluation of enteral access devices (eg, gastrostomy or jejunostomy), if present

Stool frequency and consistency

Ileostomy or colostomy output, including volume and consistency

Appetite

Affect

#### **Client history**

Personal history (eg, age, gender, race, language, education)

Medical, health, and family history

Treatments and use of complementary and alternative medicine

Social history (eg, socioeconomic status, housing situation)



## Nutrition Screening

Nutrition screening is a vital first step in determining which patients should be referred to the registered dietitian nutritionist (RDN) for nutrition assessment and care plan development. The American Society for Parenteral and Enteral Nutrition (ASPEN) defines nutrition screening as “a process to identify an individual who may be malnourished or at risk for malnutrition to determine if a comprehensive nutrition assessment and appropriate intervention are indicated.”<sup>9</sup> The Academy of Nutrition and Dietetics expands this definition to include nutrition concerns beyond malnutrition, defining nutrition screening as “the process of identifying and referring those individuals and populations who are at risk for nutrition-related problems, are appropriate for nutrition care services, and would benefit from the Nutrition Care Process.”<sup>10</sup>

Nutrition screening may be done by many health care professionals, including medical assistants, nurses, and nutrition and dietetics technicians, registered.<sup>11</sup> Physicians may also do nutrition screenings, particularly in the critical care setting.<sup>12</sup> Screening tools should be quick and easy for the clinician to use. More importantly, the tool should be valid and reliable for the population or care setting. In 2020, the Academy of Nutrition and Dietetics published a position paper on nutrition screening tools and recommended that the Malnutrition Screening Tool (MST) be used in all care settings to screen adults for malnutrition.<sup>11,13</sup> Although the MST was initially developed for the acute care setting, it has been validated in acute care, long-term care, and outpatient settings.<sup>11</sup> It has a moderate degree of validity, a moderate degree of agreement, and a moderate degree of inter-rater reliability in identifying malnutrition risk in adults, supported by Grade 1 evidence with good generalizability. Other screening tools performed well in some areas of validity but did not have Grade 1 evidence.<sup>11</sup> An MST score of 2 or greater means that the patient is at nutritional risk and should be promptly referred to an RDN for a full nutrition assessment.<sup>13</sup>

In the critical care setting, a more in-depth screening process is recommended to capture the risk of malnutrition and severity of illness, recognizing the impact of inflammation and the hypermetabolic and hypercatabolic state on nutritional status.<sup>12</sup> In the Society of Critical Care Medicine (SCCM)/ASPEN critical care guidelines, two screening tools are recommended: the Nutrition Risk Screening 2002 (NRS-2002) and the Nutrition Risk in the Critically Ill (NUTRIC) score, both of which are acceptable for use in the intensive care unit (ICU).<sup>12</sup> The NRS-2002 has two parts: The initial screening is used to identify the presence of malnutrition or risk of nutritional compromise. If the patient has a positive indicator for one of four initial screening questions, the final screening is done, which includes an assessment of nutritional risk and severity of illness to generate a risk score.<sup>14</sup> A score of 3 or higher indicates that the patient requires a full nutrition assessment and development of a nutrition care plan; a score of 5 or higher suggests that the patient is at high risk.<sup>12,14</sup> Those with high nutritional risk benefit from the initiation of early nutrition support therapy.<sup>12</sup> The NUTRIC score does not include specific nutritional measures, but it is a scoring system that includes age, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, number of comorbidities, days from hospital admission, and interleukin-6 (IL-6) level.<sup>15</sup> A score is generated from these parameters. Because IL-6 is not available at all institutions, a modified NUTRIC score has been validated for use without IL-6 to allow institutions without the means to measure this inflammatory marker to use the scoring system.<sup>16</sup> A NUTRIC score of 6 to 10, or a modified NUTRIC score of 5 to 9, suggests that the patient is at high risk for worse clinical outcomes and would benefit from aggressive nutrition support intervention.<sup>15,16</sup> The NRS-2002, NUTRIC score, and modified NUTRIC score have been validated in the ICU population, demonstrating that those at high nutritional risk benefit from early nutrition intervention with improved clinical outcomes including reduced complications (including infectious complications) and mortality.<sup>15-20</sup> Box 1.2 summarizes key elements and populations of the screening tools discussed in this section.

## **BOX 1.2**

### Nutrition Screening Tools<sup>13-16</sup>

---

#### **Malnutrition Screening Tool (MST)**

##### *Screening elements*

- Weight loss, including amount lost
- Change in appetite

##### *Recommended populations*

Adults in all care settings

---

#### **Nutrition Risk Screening 2002 (NRS-2002)**

##### *Screening elements*

Initial screening:

- BMI less than 20.5
- unintentional weight loss in the past 3 months
- reduced intake in the past week
- severe illness (in the intensive care unit [ICU])

If any element of the initial screen is positive, final screening is conducted to evaluate:

- degree of impaired nutritional status, based on degree and time frame of unintentional weight loss, BMI, and reduced intake
- severity of illness

##### *Recommended populations*

European Society for Clinical Nutrition and Metabolism (ESPEN) recommends for hospitalized patients; American Society for Parenteral and Enteral Nutrition (ASPEN) recommends for patients who are critically ill

---

#### **Nutrition Risk in the Critically Ill (NUTRIC)**

##### *Screening elements*

- Age
- Acute Physiology and Chronic Health Evaluation II (APACHE II) score
- Sequential organ failure assessment (SOFA) score
- Number of comorbidities
- Days from hospital admission to ICU admission
- Interleukin-6 (IL-6) level

##### *Recommended populations*

Patients who are critically ill; validated with and without IL-6 level

## **Food/Nutrition-Related History**

The food/nutrition-related history can include data related to dietary intake as well as such diet-related information as knowledge and beliefs about food and nutrition, medication and supplement use, and physical activity. Evaluation of usual dietary intake (ie, diet history) is an important part of the nutrition assessment. Commonly used methods for assessing food/nutrition-related history include the following:

- diet history
- 24-hour recall

- food record or diary
- food frequency questionnaire (FFQ)
- mobile health tracking applications

Each method has its advantages and disadvantages. In addition, the accuracy of these methods for predicting actual dietary intake is a matter of debate.<sup>21-23</sup>

Diet recall methods, such as the diet history and 24-hour recall, are commonly used in the clinical setting. The diet history helps the clinician assess a patient's usual dietary intake over an extended period of time, such as the past month or the past year. The 24-hour recall method estimates the patient's usual intake based on reported dietary intake in the past 24 hours. Multiple 24-hour recalls are sometimes necessary because 1 day of intake is not typically representative of usual intake.<sup>24</sup>

With food records, the patient records the types and amounts of food and beverages consumed for a predefined period of time, usually 1 to 7 days, and the clinician estimates the usual intake based on this information. Unlike the diet history and 24-hour recall methods, food records do not rely on memory.

The FFQ asks patients how many times a day, week, or year they consume certain foods (depending on the dietary component of interest). The clinician can use a patient's responses to the questionnaire to estimate intake of the dietary parameter of interest. The FFQ is often used in the research setting.

Mobile health tracking devices, including apps that can be installed on smartphones, are gaining in popularity.<sup>25</sup> A review noted that in 2017 there were 325,000 mobile health apps available in major app stores for download.<sup>26</sup> The available apps cover a wide range of monitoring tools including fitness, sleep, and food intake. Apps for tracking food intake can be much more convenient than a pen-and-paper food record or diary. Some apps offer nutrient analysis of food items by allowing the consumer to take a digital picture of the food item to be consumed, but these are still in development, and research is ongoing in this area. The apps vary in accuracy, so clinicians should be careful when using food tracking apps in a research setting.<sup>25</sup> Clinicians should also consider the patient's resources (eg, type of device and memory available for the app) and comfort level with technology before recommending a specific app for monitoring intake.<sup>27,28</sup> Knowledge of a variety of apps with different levels of complexity will allow RDNs to make app recommendations tailored to their patients' needs.

All these data-gathering methods can provide valuable information about a patient's dietary intake, which can then be compared to the patient's nutritional requirements to estimate adequacy of the diet. For patients who cannot participate in an interview (eg, patients who are critically ill requiring mechanical ventilation or patients with neurologic disorders), clinicians may need to rely on family members or caretakers to provide information about a patient's food/nutrition-related history. For patients receiving home nutrition support therapy—home enteral nutrition (EN) or parenteral nutrition (PN), or both—the home-infusion clinician may provide valuable insight into the patient's home-infusion history, including tolerance to the EN or PN regimen and ability to adhere to the infusion prescription.

In the acute care setting, calorie counts may be used to quantify oral intake. The patient may keep a food record or food diary during the hospital stay, but for patients who are ill and unable to keep these records, a family member, bedside nurse, patient care assistant, or other professional (eg, a trained food service professional) may do the monitoring. Extensive training or other innovations, such as taking pictures of food trays after a meal, may improve accuracy.<sup>29</sup> The RDN or designee then calculates energy and protein intake of the food consumed. The reliability of intake data depends on accuracy of the recorded food intake. For hospitalized patients receiving EN, monitoring of intake and output records can help identify interruptions in infusion and the need to adjust the infusion time to ensure consistent and adequate feeding.

## Biochemical Data, Medical Tests, and Procedures

Biochemical tests using blood and urine provide quantitative data about nutritional status. They can supply useful information about recent nutrient intakes and nutrient deficiencies. However, because the results of biochemical tests can be influenced by non-nutrition-related factors, such as medications, fluid status, and other metabolic processes (eg, inflammation<sup>30</sup>), these findings should be evaluated in conjunction with other nutrition assessment methods. Biochemical assessment can include the following tests<sup>8</sup>:

- protein profile (eg, albumin, prealbumin, transferrin, C-reactive protein)
- vitamin and mineral profiles
- acid-base balance
- electrolyte and renal profile
- essential fatty acid profile
- nutritional anemia profile (eg, hemoglobin, hematocrit, mean corpuscular volume, vitamin B12, folate, and iron panel)
- lipid profile
- GI profile (eg, total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, amylase, lipase)

Malabsorptive disorders are common with GI diseases. Malabsorption can involve defective digestion and absorption of carbohydrate, protein, fat, vitamins, and minerals, either in combination or independently. Biochemical tests and other procedures used in the diagnosis of malabsorptive disorders in patients with GI diseases are described in Chapter 2. Patients with malabsorptive disorders are at increased risk for vitamin and trace element deficiencies and, therefore, often require supplementation with a multivitamin, multivitamin with minerals, or individual micronutrients, depending on the location of the disorder (eg, vitamin B12 supplementation is usually required for patients with disorders that affect the terminal ileum). See Table 1.1 for laboratory tests used to assess vitamin and trace element status.<sup>31-34</sup>

Medical tests and procedures are an important part of the nutrition assessment process. For example, a computed tomography (CT) scan of the abdomen may help to identify GI complications, such as ileus or obstruction, which will help determine the patient's ability to start an oral diet or EN or the need to consider PN. A video swallow examination in a recently extubated patient can provide valuable information about the patient's ability to take an oral diet, need for a texture-modified diet, or need to continue taking nothing by mouth. The RDN should monitor for results of tests and procedures that will help develop and refine the nutrition care plan.

**TABLE 1.1** Assessment of Vitamin and Trace Element Status<sup>31-34</sup>

Nutrient	Laboratory assay	Normal values <sup>a</sup>	Signs of deficiency	Toxicity symptoms
<b>Water-soluble vitamins</b>				
Thiamin (B1)	Whole blood	>3.0-7.7 mcg/dL	Beriberi, mental confusion, Wernicke encephalopathy, congestive heart failure	Rare: irritability, headache, insomnia
Riboflavin (B2)	Erythrocyte glutathione reductase activity coefficient	<1.2	Mucositis, dermatitis, photophobia, cheilosis, normocytic anemia	Unknown
Niacin (B3)	Urinary niacin metabolites	>2 mg per g creatinine	Headaches, diarrhea, dermatitis, pellagra, memory loss	Flushing, rash, irritation, vasodilation

*Table continues*

**TABLE 1.1** Assessment of Vitamin and Trace Element Status<sup>31-34</sup> (continued)

Nutrient	Laboratory assay	Normal values <sup>a</sup>	Signs of deficiency	Toxicity symptoms
Pantothenic acid (B5)	Urinary pantothenic acid	>1 mg/dL	Fatigue, malaise, headache, insomnia	Diarrhea
Pyridoxine (B6)	Plasma pyridoxal 5'-phosphate (PLP) Urinary excretion of B6 metabolite	39-98 nmol/L >3 mcmol/d	Dermatitis, neuritis, microcytic anemia	Peripheral neuropathy
Biotin (B7)	Whole blood or serum biotin	>200 pg/mL	Dermatitis, lethargy, anorexia, alopecia, paresthesia, conjunctivitis	Unknown
Folate (B9)	Serum folate	>3 ng/mL	Megaloblastic anemia, diarrhea, lethargy	Pernicious anemia, convulsive seizures
Cyanocobalamin (B12)	Serum B12 <sup>b</sup>	170-250 pg/mL	Megaloblastic anemia, neuropathy, stomatitis, glossitis, pernicious anemia	Unknown
Ascorbic acid (C)	Plasma ascorbic acid	>0.4 mg/dL	Hemorrhaging skin, nose, gastrointestinal tract; weakness; bleeding gums; impaired wound healing	Osmotic diarrhea, oxalate kidney stones, interferes with anticoagulation therapy
Choline <sup>c</sup>	Plasma choline	≥10 mcmol/L	Fatty liver, liver damage, elevated aminotransferase	Fishy body odor, sweating, salivation, hypotension
<b>Fat-soluble vitamins</b>				
A	Serum retinol	30-100 mcg/dL	Night blindness, dermatitis, xerophthalmia, keratomalacia	Acute: nausea, vomiting, headache, dizziness, chronic peeling skin, gingivitis, alopecia
D	Serum 25-hydroxyvitamin D	≥20 ng/mL	Osteomalacia, rickets, muscle weakness	Excess bone and soft tissue calcification, kidney stones, hypercalcemia
E	Plasma or serum α-tocopherol	0.5-2.0 mg/dL	Increased platelet aggregation hemolytic anemia, neuronal axonopathy, myopathy	Impaired neutrophil function, thrombocytopenia
K	Plasma phyloquinone	0.15-1.0 mcg/L	Bleeding, purpura, bruising	Bruising, bleeding, jaundice
<b>Trace elements</b>				
Chromium	Serum value	0.05-5.0 mcg/L	Glucose intolerance, peripheral neuropathy, increased serum cholesterol, hyperlipidemia, insulin resistance	Unknown

Table continues

**TABLE 1.1** Assessment of Vitamin and Trace Element Status<sup>31-34</sup> (continued)

Nutrient	Laboratory assay	Normal values <sup>a</sup>	Signs of deficiency	Toxicity symptoms
Copper	Serum value Ceruloplasmin level	70-140 mcg/dL 20-35 mg/dL	Neutropenia, microcytic anemia, osteoporosis, decreased hair and skin pigmentation, dermatitis	Uncommon: nausea, vomiting, epigastric pain, diarrhea
Iodine <sup>d</sup>	Urine	100-199 mcg/L	Hyperplasia of thyroid, goiter, reduced metabolic rate, hypercholesterolemia	Rhinorrhea, headache, parotitis, acne
Iron	Serum ferritin	M: 40-300 mcg/L F: 20-200 mcg/L	Microcytic hypochromic anemia, pallor, koilonychia, glossitis, impaired behavioral and intellectual performance, fatigue	Cirrhosis, cardiomegaly, pancreatic damage
Manganese	Serum value	5-15 mcg/L	Nausea, vomiting, dermatitis, changes in hair color, hypocholesterolemia	Extrapyramidal symptoms, encephalitis-like symptoms, hyperirritability
Molybdenum	Neutron	0.58-0.8 mcg/L	Tachycardia, tachypnea, altered mental status, vision changes, headache, nausea, vomiting	Increased copper excretion
Selenium	Plasma or serum value	63-160 mcg/L	Muscle weakness and pain, cardiomyopathy	Hair loss, dermatitis, brittle nails, tooth decay, fatigue
Zinc	Serum value <sup>e</sup>	80-120 mcg/dL	Dermatitis, hypogeusia, diarrhea, apathy, depression, impaired wound healing	Nausea, vomiting, headache

<sup>a</sup> Reference ranges for adult patients. Reference values may vary by laboratory.

<sup>b</sup> Metabolites that result from vitamin B12 deficiency (ie, methylmalonic acid and homocysteine) may be sensitive indicators of B12 deficiency. Normal serum methylmalonic acid levels are 0.08 to 0.56 mcmol/L, and normal homocysteine levels are 5 to 15 mcmol/L.

<sup>c</sup> Although not a vitamin, choline is an essential nutrient and is, therefore, included in this table.

<sup>d</sup> Serum thyroid-stimulating hormone and free thyroxine can be used as initial screening. These surrogate markers for iodine deficiency can be used initially in place of a 24-hour urine iodine study.

<sup>e</sup> During systematic inflammatory response syndrome, serum zinc will decrease to about half of normal and remain depressed until the syndrome resolves.

## Anthropometric Measurements

Anthropometry includes measurements of body size, weight, and proportions. Anthropometric measurements used for nutrition assessment can include the following parameters<sup>8</sup>:

- height or length
- weight
- frame size
- weight change
- BMI
- growth pattern indexes or percentile ranks
- body compartment estimates (eg, fat mass, fat-free mass)

Anthropometric measures can be used, in conjunction with other assessment methods, as indicators of overall nutritional status. However, these measures are not useful for identifying specific nutrient deficiencies. Anthropometric assessments are particularly important in patients with GI disorders because wasting syndrome is a common adverse effect of the disease process.<sup>1</sup>

## Body Weight

Body weight provides a gross evaluation of overall fat and muscle stores. Ideal body weight (IBW) is often calculated using the Hamwi method<sup>35</sup>:

- Males: 106 lb for the first 5 ft in height, 6 lb for each inch taller than 5 ft
- Females: 100 lb for the first 5 ft in height, 5 lb for each inch taller than 5 ft

Usual body weight (UBW) may be a more applicable parameter to use when evaluating patients with GI dysfunction. A report of weight change may be subject to the patient's memory but can be confirmed with measured weights if a clinician has access to outpatient records. The UBW provides a useful tool for assessing changes in weight status over time. IBW and UBW may be used to evaluate the degree of overnutrition or undernutrition. Recent unintentional weight loss is a strong indicator of declining nutritional status.<sup>36</sup> Weight loss of more than 10% of UBW within a 6-month period is considered clinically significant.<sup>37</sup> Weight gain could indicate repletion of lean and fat tissue, overnutrition, or presence of edema. Percentages of IBW, UBW, and recent weight can all be used to evaluate weight status.<sup>38</sup> Assessment of weight status can be difficult in patients who are critically ill because of changes in fluid status and the challenges of correlating weight changes to fluid balance.<sup>39,40</sup> Patients who are critically ill requiring mechanical ventilation may not be able to communicate a weight history. Careful review of outpatient records, if such records are available, is essential to obtaining a weight history and determining the optimal weight to use for the nutrition assessment. For patients who are critically ill who were not weighed before volume resuscitation (eg, in severe pancreatitis), an outpatient weight that was measured closest to the ICU admission date may be a more appropriate weight to use for assessment.

### Percentage of Ideal Body Weight

To calculate a patient's percentage of IBW, divide the current weight by the IBW and multiply the result by 100. The results are interpreted as follows<sup>38</sup>:

- mild malnutrition: 80% to 90% of IBW
- moderate malnutrition: 70% to 79.9% of IBW
- severe malnutrition: less than 70% of IBW

### Percentage of Usual Body Weight

To calculate a patient's percentage of UBW, divide the current weight by the UBW and multiply the result by 100. The results are interpreted as follows<sup>38</sup>:

- mild malnutrition: 85% to 95% of UBW
- moderate malnutrition: 75% to 84.9% of UBW
- severe malnutrition: less than 75% of UBW

---

\* Specific recommendations for transgender people were not provided.



## Time Frame of Weight Change

The time frame of weight loss is an important part of the assessment of percentage of UBW. The clinician should obtain the time frame of the weight change either from the patient interview or from documented weight records. After calculating the percentage of UBW, the time frame of weight change should be interpreted as follows:

$$\% \text{ Weight Change} = \frac{(\text{Usual body weight} - \text{Current body weight})}{\text{Usual body weight}} \times 100$$

The results are interpreted as follows<sup>38</sup>:

- *Significant weight loss* is defined as 1% to 2% in 1 week; 5% in 1 month; 7.5% in 3 months; or 10% in 6 months.
- *Severe weight loss* is defined as weight loss that exceeds the preceding amounts.

## BMI

BMI is commonly used to classify weight status and assess healthy weight, malnutrition, and obesity. It is calculated using relative weight for height (as shown in the following equations) and is significantly correlated with total body fat content.<sup>41</sup>

$$\text{BMI} = \frac{\text{Weight in kg}}{(\text{Height in m})^2}$$

or

$$\text{BMI} = \frac{\text{Weight in lb}}{(\text{Height in inches})^2} \times 703$$

Guidelines for interpretation of BMI in adults are presented in Table 1.2.<sup>41,42</sup> For children and adolescents aged 19 years and younger, assessment of BMI is age- and gender-specific. Refer to the appropriate reference tables available from the Centers for Disease Control and Prevention ([www.cdc.gov/growthcharts](http://www.cdc.gov/growthcharts)).

**TABLE 1.2** Interpretation of Body Mass Index in Adults<sup>41,42</sup>

BMI	Classification
≤15.9	Severe thinness
16.0-16.9	Moderate thinness
17.0-18.4	Mild thinness
18.5-24.9	Normal weight
25.0-29.9	Overweight
30.0-34.9	Obesity class I
35.0-39.9	Obesity class II
≥40	Obesity class III



## Nutrition Focused Physical Findings

### Body Composition

Historically, body composition (ie, fat mass and fat-free mass) has been estimated using skinfold measurements, such as midarm circumference, midarm muscle circumference, and skinfold thickness. Although not frequently used in the clinical setting, skinfold measurements (serial measures) can be used to evaluate changes in lean and fat mass over time in individual patients. Other methods for clinical evaluation of body composition include dual-energy x-ray absorptiometry (DXA), ultrasound (US), and bioelectrical impedance analysis (BIA). Recent clinical guidelines published by ASPEN recommend DXA for the evaluation of fat mass only, because validity of use for the evaluation of lean body mass is still unknown. Guidelines for the use of US and BIA could not be provided.<sup>43</sup> CT has been used in the research setting and may also be used in the clinical setting, by appropriately trained practitioners, to evaluate fat and muscle mass.<sup>44</sup>

### Waist Circumference

Waist circumference is an assessment of abdominal fat. It is measured (in inches or centimeters) by placing a standard measuring tape around the bare abdomen just above the hip bone. Independent of BMI, a high waist circumference is a risk factor for several diseases, including diabetes, hyperlipidemia, hypertension, and cardiovascular disease. A waist circumference of more than 40 inches (102 cm) in men and more than 35 inches (88 cm) in women is associated with increased disease risk.<sup>45</sup>

Nutrition focused physical findings are described as “nutrition-related physical characteristics associated with pathophysiological states derived from a nutrition focused physical examination, interview, or the medical record.” These findings are examined to assess overall physical appearance, muscle and subcutaneous fat wasting, swallow function, appetite, and affect. Signs and symptoms of micronutrient deficiencies as well as essential fatty acid deficiency, which may be of significant concern in patients with GI disorders, may be identified during the nutrition focused physical examination. See Box 1.3 for clinical findings from the physical examination associated with nutrient deficiencies. Both subjective and objective physical findings are assessed during the nutrition focused physical examination, which includes evaluations of the following factors and systems<sup>8</sup>:

- overall appearance
- body language
- cardiovascular-pulmonary system (eg, edema, shortness of breath)
- extremities, muscles, and bones
- GI system (mouth to rectum)
- head and eyes
- nerves and cognition
- skin
- vital signs (eg, blood pressure, heart rate, temperature)

The nutrition focused physical examination may be limited in patients who are critically ill, particularly the evaluation of extremities, muscles, and bones. The presence of an endotracheal tube, tracheostomy, central venous catheters, orogastric or nasogastric tubes, or compression boots may make it difficult for the RDN to conduct a comprehensive evaluation. Coordination with the patient’s bedside nurse to assist with the examination or to plan the examination for times when the patient is being turned to evaluate for pressure injuries or while being washed may allow for a more comprehensive examination.

## **BOX 1.3**

### Clinical Findings From Physical Examination Associated With Nutrient Deficiencies

---

#### **Hair**

<i>Clinical findings</i>	<i>Possible deficiency</i>
Alopecia	Protein
Dry, dull, lackluster, brittle, sparse	Protein, iron, zinc, essential fatty acids
Dyspigmentation	Biotin, protein
Flag sign (alternating bands of light and dark hair)	Protein

---

#### **Skin and nails**

<i>Clinical findings</i>	<i>Possible deficiency</i>
Xerosis	Vitamin A, essential fatty acids
Follicular hyperkeratosis	Vitamin A, essential fatty acids
Perifollicular petechiae	Vitamin C, vitamin K
Dermatitis	Essential fatty acids, niacin, riboflavin, zinc
Pallor	Iron, folate, vitamin B12
Nasolabial seborrhea	Niacin, riboflavin, vitamin B6
Koilonychia	Iron

---

#### **Eyes**

<i>Clinical findings</i>	<i>Possible deficiency</i>
Xerophthalmia	Vitamin A
Bitot spots	Vitamin A
Night blindness	Vitamin A
Angular palpebritis	Riboflavin

---

#### **Mouth**

<i>Clinical findings</i>	<i>Possible deficiency</i>
Cheilosis	Vitamin B6, riboflavin, niacin
Angular stomatitis	Riboflavin, vitamin B6, iron
Bleeding or spongy gums	Vitamin C
Magenta tongue	Riboflavin
Atrophic papillae	Iron, niacin, folate, vitamin B12
Glossitis	Niacin, folate, iron, vitamin B6, vitamin B12
Dysgeusia	Zinc

*Box continues*

## BOX 1.3 (CONTINUED)

### Cardiovascular

#### *Clinical findings*

Irregular or abnormal rhythm or rate

#### *Possible deficiency*

Potassium excess or deficiency, calcium or phosphorus deficiency, magnesium deficiency or excess

### Musculoskeletal

#### *Clinical findings*

Muscle wasting

Bowlegs

Beading of ribs

#### *Possible deficiency*

Protein-energy malnutrition

Vitamin D, calcium

Vitamin D, protein-energy malnutrition

### Neurologic

#### *Clinical findings*

Mental confusion

Dementia

#### *Possible deficiency*

Thiamin, vitamin B12, vitamin B6

Niacin, vitamin B12

## Client History

The client history includes information related to personal, medical, family, and social history with the potential to affect nutritional status. Box 1.4 outlines the data to be included in the client history.<sup>8</sup>

## Assessment of Energy Requirements

### *Patients Who Are Critically Ill*

Patients who are critically ill have unique metabolic alterations compared to patients who are noncritically ill and ambulatory. These changes are summarized in Box 1.5. Patients who are critically ill have higher protein losses and increased metabolic demand for protein. Protein losses can be minimized but not completely abolished with nutrition support therapy alone.<sup>46</sup> The goals of nutrition support therapy for the patient who is critically ill are to minimize protein loss, maintain immune function, avoid metabolic complications, and attenuate the metabolic response to stress.<sup>12</sup> An accurate assessment of energy requirements is an important step in meeting these goals.

Underfeeding or overfeeding patients who are critically ill can lead to significant complications. Underfeeding calories can lead to impaired immune response, muscle catabolism, poor wound healing (particularly for surgical patients), and development of pressure injuries. Overfeeding can lead to hyperglycemia, hyperinsulinemia, hypokalemia, hypophosphatemia, excess carbon dioxide production, difficulty weaning from the ventilator, hepatic steatosis, and azotemia.<sup>47,48</sup> Indirect calorimetry is used to calculate energy expenditure by measurement of respiration gas exchange (oxygen consumption and carbon dioxide production) and is considered the gold standard for assessing energy requirements, particularly in patients who are critically ill.<sup>49</sup> Measuring energy expenditure can help to avoid the complications associated with underfeeding or overfeeding. Because the equipment used to conduct indirect calorimetry is expensive and requires technical expertise, its use in the clinical setting is limited. For clinicians without access to indirect calorimetry, predictive equations are necessary to determine energy requirements for the patient who is critically ill.

## **BOX 1.4**

### Data to Include in a Client History<sup>8</sup>

#### **Personal history**

Age, gender, sex, race  
Ethnicity  
Language  
Literacy factors  
Education  
Role in family  
Tobacco use  
Physical disability  
Mobility

#### **Medical history**

Chief nutrition complaint  
Cardiovascular  
Endocrine, metabolic  
Excretory  
Gastrointestinal  
Gynecologic  
Hematologic, oncologic

Immunologic  
Musculoskeletal  
Neurologic  
Psychological

#### **Treatments and therapy**

Medical treatment, medical therapy  
Surgical treatment  
Palliative care, end-of-life care

#### **Family and social history**

Socioeconomic status  
Living and housing situation  
Domestic issues  
Social and medical support  
Geographic location of home  
Occupation  
Religion  
History of recent crisis  
Daily stress level

## **BOX 1.5**

### Metabolic Changes During Critical Illness

#### **Shock or resuscitation phase**

Low cardiac output  
Hypotension  
Poor tissue perfusion  
Reduced oxygen consumption

#### **Acute catabolic phase**

Glycogenolysis  
Gluconeogenesis  
Proteolysis  
Increased oxygen consumption  
Increased carbon dioxide production  
Hypermetabolism  
Hyperglycemia  
Overall catabolism

#### **Anabolic phase**

Energy expenditure returns to normal  
Normoglycemia  
Anabolism

According to the Academy of Nutrition and Dietetics 2012 Critical Illness Evidence-Based Nutrition Practice Guideline,<sup>50</sup> the Penn State University (PSU) 2003b equation for resting metabolic rate (RMR) has the highest prediction accuracy and should be used in nonobese, critically ill, mechanically ventilated adults. See Box 1.6 for this equation.<sup>51</sup>

## **BOX 1.6**

### Estimating Energy Requirements for Adults Who Are Mechanically Ventilated and Without Obesity<sup>51</sup>

#### **Penn State University 2003b Equation**

$$\text{RMR} = \text{Mifflin} (0.96) + V_E (31) + T_{\text{max}} (167) - 6,212$$

Where RMR is resting metabolic rate, Mifflin is Mifflin-St. Jeor RMR equation (see Box 1.9),  $V_E$  is minute ventilation in L/min, and  $T_{\text{max}}$  is maximum temperature over previous 24 hours in degrees Celsius.

According to the Academy of Nutrition and Dietetics 2012 Critical Illness Evidence-Based Nutrition Practice Guideline, the PSU 2003b equation has the highest prediction accuracy in critically ill, mechanically ventilated adults with obesity who are aged 60 years or less. However, for patients who are obese aged 60 years or older, the PSU 2010 equation has the highest prediction accuracy.<sup>50</sup> See Box 1.7 for the PSU 2010 equation.<sup>52</sup>

## **BOX 1.7**

### Estimating Energy Requirements for Adults With Obesity Who Are Mechanically Ventilated<sup>52</sup>

#### **Penn State University 2010 Equation**

$$\text{RMR} = \text{Mifflin} (0.71) + V_E (64) + T_{\text{max}} (85) - 3,085$$

Where RMR is resting metabolic rate, Mifflin is Mifflin-St. Jeor RMR equation (see Box 1.9),  $V_E$  is minute ventilation in L/min, and  $T_{\text{max}}$  is maximum temperature over previous 24 hours in degrees Celsius.

The SCCM and ASPEN have published guidelines for estimating energy requirements in patients who are critically ill as well. Both societies advocate the use of indirect calorimetry, but many institutions do not have access to this technology. The societies recommend a simplified, weight-based method for determining energy requirements. For nonobese adults, 25 to 30 kcal/kg is recommended. Hypocaloric, high-protein feeding is recommended for critically ill obese patients to help avoid specific complications, such as hyperglycemia and excessive carbon dioxide production while preserving lean body mass.<sup>12</sup> For patients with a BMI of 30 to 50, energy requirements should be calculated using 11 to 14 kcal/kg of actual weight, and for patients with a BMI of greater than

50, energy requirements should be calculated using 22 to 25 kcal/kg of IBW.<sup>12,53</sup> Interestingly, a secondary data analysis found no significant difference in mortality or time to discharge alive in a large cohort (n=5,672) of patients who are critically ill whose energy requirements were calculated using complex equations vs weight-based equations.<sup>54</sup>

### *Patients Who Are Noncritically Ill*

In patients who are noncritically ill, basal energy expenditure (BEE) can be estimated using predictive equations, as an alternative to indirect calorimetry. The Harris-Benedict equation<sup>55</sup> is one of the oldest and most widely used predictive equations for calculating BEE. See Box 1.8.

#### **BOX 1.8**

##### Harris-Benedict Equation

$$\text{Male: BEE} = 66 + (13.7 \times W) + (5 \times H) - (6.8 \times A)$$

$$\text{Female: BEE} = 655 + (9.6 \times W) + (1.7 \times H) - (4.7 \times A)$$

Where BEE is basal energy expenditure, W is body weight in kg, H is height in cm, and A is age in years.

In addition, estimated energy needs may be based on RMR, as calculated by the Mifflin-St. Jeor equation.<sup>6</sup> See Box 1.9.

#### **BOX 1.9**

##### Mifflin-St. Jeor Equation

$$\text{Male: RMR} = (9.99 \times W) + (6.25 \times H) - (4.92 \times A) + 5$$

$$\text{Female: RMR} = (9.99 \times W) + (6.25 \times H) - (4.92 \times A) - 161$$

Where W is body weight in kg, H is height in cm, and A is age in years.

This equation seems to be the most accurate for estimation of energy needs among individuals who are obese and nonobese who are not critically ill.<sup>57</sup>

## **Assessment of Protein Requirements**

### *Protein Requirements*

In healthy individuals, the Recommended Dietary Allowance for protein in men and women\* is 0.8 g/kg/d.<sup>58</sup> Estimated protein requirements may be based on specific disease states or metabolic stress states and may increase to levels of up to 2 g/kg/d depending on level of

---

\* Specific recommendations for transgender people were not provided.

hypermetabolism, stress, and exogenous losses.<sup>59</sup> The body of a 70-kg male includes approximately 11 kg protein, with about 43% of it in the form of skeletal muscle.<sup>60</sup>

The rate of endogenous protein breakdown (catabolism) decreases during energy deprivation. An unstressed individual loses approximately 12 to 18 g protein per day after about 10 days of starvation, which equates to approximately 2 oz (57 g) of muscle tissue (2 to 3 g nitrogen). During metabolic stress, protein breakdown increases exponentially to approximately 30 to 60 g/d after surgery, 60 to 90 g/d with infection, 100 to 130 g/d with severe sepsis, and more than 175 g/d with burns or head injuries.<sup>61</sup> In chronic illness, skeletal muscle becomes the largest single contributor to protein loss.<sup>62</sup> The SCCM and ASPEN recommend a protein intake of 1.2 to 2 g/kg for patients who are critically ill. For patients who are critically ill who are obese, the societies recommend using IBW for calculations and providing at least 2 g/kg IBW for patients with class I and II obesity and at least 2.5 g/kg IBW for patients with class III obesity.<sup>12</sup>

## Nitrogen Balance

Nitrogen balance studies are sometimes used to evaluate the adequacy of protein intake. Nitrogen balance studies indicate the relationship between protein intake and nitrogen removal from the renal system. Positive nitrogen balance cannot confirm anabolism because it lacks the specificity of stable isotopic amino acid studies.<sup>63,64</sup> The conversion factor commonly used for dietary protein is 6.25 g nitrogen per 1 g protein. Accurate 24-hour urine collection is difficult to obtain, and significant error may consequently be introduced into nitrogen balance calculations. See Box 1.10.

### BOX 1.10

#### Nitrogen Balance Calculation

$$\begin{aligned} \text{Nitrogen balance (g/d)} &= \text{nitrogen intake (g/d)} - \text{nitrogen loss (g/d)} \\ &= \frac{(\text{Protein Intake})}{6.25} - \left[ \frac{\text{UUN (g/d)}}{0.8} + 2.5 \text{ g} \right] \end{aligned}$$

Where UUN = urine urea nitrogen, UUN/0.8 represents UUN + urinary nonurea nitrogen, and 2.5 is the sum of fecal and integumental nitrogen.

## Hepatic Transport Proteins

Historically, hepatic transport proteins have been used as markers of malnutrition. Low levels of these acute-phase proteins are correlated with morbidity and mortality.<sup>30</sup> These proteins are useful prognostic indicators of severity of illness, but they should not be used routinely as the primary diagnostic marker of malnutrition. Synthesis of acute-phase proteins (eg, albumin, transferrin, prealbumin, and retinol-binding protein) decreases precipitously during inflammatory conditions. Positive acute-phase proteins (C-reactive protein) increase in concentration during acute and chronic inflammatory states. Elevation of C-reactive protein may be used to confirm inflammatory status.<sup>30,65</sup>

## Nutrition Assessment Tools

Numerous tools are available for general assessment of nutritional status. In the clinical setting, one of the most commonly used and validated assessment tools is the subjective global assessment (SGA).

The SGA (see Figure 1.1) is a nutrition assessment tool used to measure nutritional status on the basis of weight, dietary intake, GI symptoms, functional capacity, and physical examination findings.<sup>37</sup> Nutritional status is categorized as well-nourished, moderately

**FIGURE 1.1** The subjective global assessment

(Select appropriate category with a checkmark, or enter numerical value where indicated by “#.”)

**A. History**

**1. Weight change**

Overall loss in past 6 months: amount = # \_\_\_\_\_ kg; % loss = # \_\_\_\_\_

Change in past 2 weeks: \_\_\_\_\_ increase,

\_\_\_\_\_ no change,

\_\_\_\_\_ decrease.

**2. Dietary intake change (relative to normal)**

\_\_\_\_\_ No change,

\_\_\_\_\_ Change \_\_\_\_\_ duration = # \_\_\_\_\_ weeks

\_\_\_\_\_ type: \_\_\_\_\_ suboptimal liquid diet, \_\_\_\_\_ full liquid diet

\_\_\_\_\_ hypocaloric liquids, \_\_\_\_\_ starvation.

**3. Gastrointestinal symptoms (that persisted for >2 weeks)**

\_\_\_\_\_ none, \_\_\_\_\_ nausea, \_\_\_\_\_ vomiting, \_\_\_\_\_ diarrhea, \_\_\_\_\_ anorexia.

**4. Functional capacity**

\_\_\_\_\_ No dysfunction (eg, full capacity),

\_\_\_\_\_ Dysfunction \_\_\_\_\_ duration = # \_\_\_\_\_ weeks.

\_\_\_\_\_ type: \_\_\_\_\_ working suboptimally

\_\_\_\_\_ ambulatory,

\_\_\_\_\_ bedridden.

**5. Disease and its relation to nutritional requirements**

Primary diagnosis (specify) \_\_\_\_\_

Metabolic demand (stress): \_\_\_\_\_ no stress, \_\_\_\_\_ low stress,

\_\_\_\_\_ moderate stress, \_\_\_\_\_ high stress.

**B. Physical (for each trait specify: 0 = normal, 1+ = mild, 2+ = moderate, 3+ = severe).**

# \_\_\_\_\_ loss of subcutaneous fat (triceps, chest)

# \_\_\_\_\_ muscle wasting (quadriceps, deltoids)

# \_\_\_\_\_ ankle edema

# \_\_\_\_\_ sacral edema

# \_\_\_\_\_ ascites

**C. SGA rating (select one)**

\_\_\_\_\_ A = Well nourished

\_\_\_\_\_ B = Moderately (or suspected of being) malnourished

\_\_\_\_\_ C = Severely malnourished

Adapted with permission from Detsky AJ, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? *JPEN J Parenter Enteral Nutr.* 1987;11:8-14.<sup>37</sup>

malnourished (or suspected of being malnourished), or severely malnourished. The SGA was originally developed for patients with GI disease.<sup>14</sup> It has since been validated and used clinically for many patient populations and is widely accepted as a practical and reliable tool for nutrition assessment.<sup>66</sup>

## Documenting Malnutrition

Malnutrition is a diagnosis known to be associated with poor outcomes in individuals who are hospitalized and nonhospitalized. A joint task force of the Academy of Nutrition and Dietetics and ASPEN has recommended a standardized set of diagnostic characteristics to identify and document adult malnutrition (see Table 1.3).<sup>67</sup> A 2019 review evaluated the usability of these diagnostic characteristics in day-to-day practice and their association with clinical outcomes.<sup>68</sup> Many of the diagnostic characteristics are readily available to clinicians during nutrition assessment, and the use of this framework to assess the presence of malnutrition has been predictive of length of hospital stay, morbidity, and mortality. A large validation study led by the Academy of Nutrition and Dietetics is in progress.



**TABLE 1.3** Clinical Characteristics That Support a Diagnosis of Malnutrition<sup>a,67</sup>

Clinical characteristic	Malnutrition in the context of acute illness or injury		Malnutrition in the context of chronic illness		Malnutrition in the context of social or environmental circumstances			
	Moderate malnutrition	Severe malnutrition	Moderate malnutrition	Severe malnutrition	Nonsevere (moderate) malnutrition	Severe malnutrition		
<p><b>(1) Energy intake</b></p> <p>Malnutrition is the result of inadequate food and nutrient intake or assimilation; thus, recent intake compared to estimated requirements is a primary criterion defining malnutrition. The clinician may obtain or review the food and nutrition history, estimate optimum energy needs, compare them with estimates of energy consumed, and report inadequate intake as a percentage of estimated energy requirements over time.</p>	<75% of estimated energy requirement for >7 d	≤50% of estimated energy requirement for ≥5 d	<75% of estimated energy requirement for ≥1 mo	≤75% of estimated energy requirement for ≥1 mo	<75% of estimated energy requirement for ≥3 mo	≤50% of estimated energy requirement for ≥1 mo		
	%	Time	%	Time	%	Time	%	Time
<p><b>(2) Interpretation of weight loss</b></p> <p>The clinician may evaluate weight in light of other clinical findings, including the presence of under- or overhydration. The clinician may assess weight change over time reported as a percentage of weight lost from baseline.</p>	1-2	1 wk	5	1 mo	5	1 mo	>5	1 mo
	%	Time	%	Time	%	Time	%	Time
<p><b>Physical findings:</b></p> <p>Malnutrition typically results in changes to the physical examination and document any one of the findings below as an indicator of malnutrition.</p>								
<p><b>(3) Body fat</b></p> <p>Loss of subcutaneous fat (eg, orbital, triceps, fat overlying the ribs)</p>	Mild	Moderate	Mild	Severe	Mild	Severe		
	Mild	Moderate	Mild	Severe	Mild	Severe		

Table continues

**TABLE 1.3** Clinical Characteristics That Support a Diagnosis of Malnutrition<sup>a,67</sup> (continued)

Clinical characteristic	Malnutrition in the context of acute illness or injury		Malnutrition in the context of chronic illness		Malnutrition in the context of social or environmental circumstances	
	Moderate malnutrition	Severe malnutrition	Moderate malnutrition	Severe malnutrition	Nonsevere (moderate) malnutrition	Severe malnutrition
(4) <b>Muscle mass</b> Muscle loss (eg, wasting of the temples [temporalis muscle]; clavicles [pectoralis and deltoids]; shoulders [deltoids]; interosseous muscles; scapula [latissimus dorsi, trapezius, deltoids]; thigh [quadriceps]; and calf [gastrocnemius])	Mild	Moderate	Mild	Severe	Mild	Severe
(5) <b>Fluid accumulation</b> The clinician may evaluate generalized or localized fluid accumulation evident on examination (extremities; vulvar or scrotal edema or ascites). Weight loss is often masked by generalized fluid retention (edema), and weight gain may be observed.	Mild	Moderate to severe	Mild	Severe	Mild	Severe
(6) <b>Reduced grip strength</b> The clinician should consult normative standards supplied by the manufacturer of the measurement device.	N/A <sup>b</sup>	Measurably reduced	N/A	Measurably reduced	N/A	Measurably reduced

<sup>a</sup> The presence of at least two of the six characteristics is recommended for diagnosis of either severe or nonsevere malnutrition. Height and weight should be measured rather than estimated to determine body mass index. Usual weight should be obtained to determine the percentage and interpret the significance of weight loss. Basic indicators of nutritional status, (eg, body weight, weight change, and appetite) may substantively improve with refeeding in the absence of inflammation. Refeeding or nutrition support, or both, may stabilize but not significantly improve nutrition parameters in the presence of inflammation. The National Center for Health Statistics defines a chronic disease or condition as one lasting 3 months or longer. Serum proteins, such as albumin and prealbumin, are not included as defining characteristics of malnutrition because recent evidence analysis shows that serum levels of these proteins do not change in response to changes in nutrient intake.

<sup>b</sup> N/A = not applicable.

Adapted with permission from White JV, Guenter P, Jensen G, et al. Consensus statement of the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *J Acad Nutr Diet.* 2012; 112(5):730-738.<sup>67</sup>

A modified tool for assessing malnutrition has been developed by a working group spearheaded by ASPEN and the European Society for Clinical Nutrition and Metabolism.<sup>69</sup> The group found that there was no framework for identifying malnutrition that was accepted on a global scale. The members evaluated various malnutrition criteria to develop a simplified framework for identifying malnutrition that was then developed and accepted by a global group of clinical nutrition experts. The key characteristics include the evaluation of phenotypic criteria (weight change, BMI, and reduced muscle mass) and etiologic criteria (reduced food intake or assimilation, and inflammation). After identifying the initial phenotypic and etiologic criteria, clinicians can then determine severity of malnutrition (See Boxes 1.11 and 1.12). Validation studies are in progress to determine if this assessment framework can identify such clinically relevant outcomes as prolonged length of hospital stay, morbidity, and mortality on a global scale.<sup>70</sup>

### **BOX 1.11**

Global Leadership Initiative in Malnutrition: Phenotypic and Etiologic Criteria for the Diagnosis of Malnutrition<sup>69</sup>

#### **Phenotypic criteria**

##### *Weight loss (%)*

More than 5% within past 6 months or more than 10% beyond 6 months

##### *Low BMI*

Less than 20 if aged 70 years or less, or less than 22 if aged more than 70 years

Asian populations: Less than 18.5 if aged 70 years or less, or less than 20 if aged more than 70 years

##### *Reduced muscle mass*

Reduced by validated body composition measuring techniques

#### **Etiologic criteria**

##### *Reduced food intake or assimilation*

50% or less of energy requirements for more than 1 week, or any reduction for more than 2 weeks, or any chronic gastrointestinal condition that adversely affects food assimilation or absorption

##### *Inflammation*

Acute disease or injury, or chronic disease-related

## BOX 1.12

Thresholds for Severity Grading of Malnutrition Into Stage 1 (Moderate) and Stage 2 (Severe) Malnutrition<sup>69</sup>

<sup>a</sup>One phenotypic criterion is required to meet a particular grade of malnutrition.

<sup>b</sup>Further research is needed to secure consensus reference BMI data for Asian populations in clinical settings.

### Stage 1 (moderate)

Weight loss (%)

### Phenotypic criteria<sup>a</sup>

5% to 10% within the past 6 months, or 10% to 20% beyond 6 months

Low BMI<sup>b</sup>

Less than 20 if aged 70 years or less or less than 22 if aged 70 years or more

Reduced muscle mass

Mild-to-moderate deficit (using validated assessment methods)

### Stage 2 (severe)

Weight loss (%)

More than 10% within the past 6 months, or more than 20% beyond 6 months

Low BMI<sup>b</sup>

Less than 18.5 if aged 70 years or less, or less than 10 if aged 70 years or more

Reduced muscle mass

Severe deficit (using validated assessment methods)

## Summary

The GI tract is essential for the absorption and digestion of foods, and disorders of the GI system can have a significant impact on dietary intake and nutritional status. Nutrition assessment plays a vital role in identifying nutrition-related problems in patients with GI disorders and in developing appropriate nutrition interventions. A complete nutrition assessment includes evaluating dietary data, biochemical test and procedure results, anthropometric measures, nutrition focused physical findings, and the personal, medical, and social history, with an ultimate goal of improving clinical outcomes in patients with GI disorders.

## References

1. Fisher RL. Wasting in chronic gastrointestinal diseases. *J Nutr.* 1999;129(1S suppl):252S-255S.
2. Correia MI, Waitzberg DL. The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. *Clin Nutr.* 2003;22(3):235-239.
3. Goiburu ME, Goiburu MM, Bianco H, et al. The impact of malnutrition on morbidity, mortality and length of hospital stay in trauma patients. *Nutr Hosp.* 2006;21(5):604-610.
4. Mogensen KM, Robinson MK, Casey JD, et al. Nutritional status and mortality in the critically ill. *Crit Care Med.* 2015;43(12):2605-2615.
5. Robinson MK, Mogensen KM, Casey JD, et al. The relationship among obesity, nutritional status, and mortality in the critically ill. *Crit Care Med.* 2015;43(1):87-100.
6. Mogensen KM, Horkan CM, Purtle SW, et al. Malnutrition, critical illness survivors, and post-discharge outcomes: a cohort study. *JPEN J Parenter Enteral Nutr.* 2018;42(3):557-565.
7. Mueller C, Compher C, Druyan ME, et al. A.S.P.E.N. Clinical guidelines: nutrition screening, assessment, and intervention in adults. *JPEN J Parenter Enteral Nutr.* 2011;35(1):16-24.
8. Academy of Nutrition and Dietetics. Electronic Nutrition Care Process Terminology (eNCPT). Accessed January 31, 2021. [www.ncpro.org/pubs/2020-encpt-en?](http://www.ncpro.org/pubs/2020-encpt-en?)

9. Robinson D, Walker R, Adams SC, et al. American Society for Parenteral and Enteral Nutrition (ASPEN) definitions of terms, style, and conventions used in ASPEN Board of Directors—approved documents. May 2018. Accessed April 30, 2021. [www.nutritioncare.org/uploadedFiles/Documents/Guidelines\\_and\\_Clinical\\_Resources/ASPEN%20Definition%20of%20Terms,%20Style,%20and%20Conventions%20Used%20in%20ASPEN%20Board%20of%20Directors%E2%80%93Approved%20Documents.pdf](http://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/ASPEN%20Definition%20of%20Terms,%20Style,%20and%20Conventions%20Used%20in%20ASPEN%20Board%20of%20Directors%E2%80%93Approved%20Documents.pdf)
10. Academy of Nutrition and Dietetics. Definition of terms list. February 2021. Accessed April 30, 2021. [www.eatrightpro.org/-/media/eatrightpro-files/practice/scope-standards-of-practice/academydefinitionoftermslist.pdf?la=en&hash=9C69653783C7F39EA2E0E4F9E6745A6D9343D32A](http://www.eatrightpro.org/-/media/eatrightpro-files/practice/scope-standards-of-practice/academydefinitionoftermslist.pdf?la=en&hash=9C69653783C7F39EA2E0E4F9E6745A6D9343D32A)
11. Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition and Dietetics: Malnutrition (undernutrition) screening for all adults. *J Acad Nutr Diet*. 2020;120(4):709-713.
12. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). *JPEN J Parenter Enteral Nutr*. 2016;40(2):159-211.
13. Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute care hospitals. *Nutrition*. 1999;15(6):458-464.
14. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. *Clin Nutr*. 2003;22(4):415-421.
15. Heyland DK, Dhaliwal R, Jiang X, Day AG. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. *Crit Care*. 2011;15(6):R268.
16. Rahman A, Hasan RM, Agarwala R, Martin C, Day AG, Heyland DK. Identifying critically-ill patients who will benefit most from nutritional therapy: further validation of the “modified NUTRIC” nutrition risk assessment tool. *Clin Nutr*. 2016;35(1):158-162.
17. Jie B, Jiang ZM, Nolan MT, Zhu SN, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. *Nutrition*. 2012;28(10):1022-1027.
18. Maciel LRMA, Franzosi OS, Nunes DLS, et al. Nutrition Risk Screening 2002 cut-off to identify high-risk is a good predictor of ICU mortality in critically ill patients. *Nutr Clin Pract*. 2019;34(1):137-141.
19. Mendes R, Policarpo S, Fortuna P, et al. Nutritional risk assessment and cultural validation of the modified NUTRIC score in critically ill patients—a multicenter prospective cohort study. *J Crit Care*. 2017;37:45-49.
20. Mayr U, Pfau J, Lukas M, et al. NUTRIC and modified NUTRIC are accurate predictors of outcome in end-stage liver disease: a validation in critically ill patients with liver cirrhosis. *Nutrients*. 2020;12(7):2134.
21. Schaefer EJ, Augustin JL, Schaefer MM, et al. Lack of efficacy of a food frequency questionnaire in assessing dietary macronutrient intakes in subjects consuming diets of known composition. *Am J Clin Nutr*. 2000;71(3):746-751.
22. Willett WC, ed. *Nutritional Epidemiology*. 2nd ed. Oxford University Press; 1998.
23. Buzzard IM, Faucett CL, Jeffery RW, et al. Monitoring dietary change in a low-fat diet intervention study: advantages of using 24-hour dietary recalls vs food records. *J Am Diet Assoc*. 1996;96(6):574-579.
24. Buzzard M. 24-hour recall and food record methods. In: Willett WC, ed. *Nutritional Epidemiology*. 2nd ed. Oxford University Press; 1998:50-73.
25. Zhang L, Misir A, Boshuizen H, Ocke M. A systematic review and meta-analysis of validation studies performed on dietary record apps. *Adv Nutr*. 2021;12(6):2321-2332.
26. Ferrara G, Kim J, Lin S, Hua J, Seto E. A focused review of smartphone diet-tracking apps: usability, functionality, coherence with behavior change theory, and comparative validity of nutrient intake and energy estimates. *JMIR Mhealth Uhealth*. 2019;7(5):e9232.
27. Kelly JT, Collins PF, McCamley J, Ball L, Roberts S, Campbell KL. Digital disruption of dietetics: are we ready? *J Hum Nutr Diet*. 2021;34(1):134-146.
28. Chen J, Gemming L, Hanning R, Allman-Farinelli M. Smartphone apps and the nutrition care process: current perspectives and future considerations. *Patient Educ Couns*. 2018;101(4):750-757.
29. Sullivan SC, Bopp MM, Weaver DL, et al. Innovations in calculating precise nutrient intake of hospitalized patients. *Nutrients*. 2016;8:412.
30. Evans DC, Corkins MR, Malone A, et al. The use of visceral proteins as nutrition markers: an ASPEN position paper. *Nutr Clin Pract*. 2021;36(1):22-28.
31. Mordarski B. *Nutrition Focused Physical Exam*. 3rd ed. Academy of Nutrition and Dietetics; 2022.
32. Clark FS. Vitamin and trace elements. In: Gottschlich MM, ed. *The ASPEN Nutrition Support Core Curriculum: A Case-Based Approach—The Adult Patient*. American Society for Parenteral and Enteral Nutrition; 2007:129-159.
33. Pesce-Hammond K, Wessel J. Nutrition assessment and decision making. In: Merritt R, ed. *The ASPEN Nutrition Support Practice Manual*. American Society for Parenteral and Enteral Nutrition; 2005.
34. McKeever L. Vitamins and trace elements. In: Mueller CM, ed. *The ASPEN Adult Nutrition Support Core Curriculum*. 3rd ed. American Society for Parenteral and Enteral Nutrition; 2017:139-182.
35. Hamwi G. Changing dietary concepts. In: Danowski TS, ed. *Diabetes Mellitus: Diagnosis and Treatment*. American Diabetes Association; 1964.
36. Kyle UG, Genton L, Pichard C. Hospital length of stay and nutritional status. *Curr Opin Clin Nutr Metab Care*. 2005;8(4):397-402.
37. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? *JPEN J Parenter Enteral Nutr*. 1987;11:8-14.



38. Blackburn GL, Bisttian BR, Maini BS, et al. Nutritional and metabolic assessment of the hospitalized patient. *JPEN J Parenter Enteral Nutr.* 1977;11(1):11-22.
39. Schneider AG, Baldwin I, Freitag E, et al. Estimation of fluid status changes in critically ill patients: fluid balance chart or electronic bed weight? *J Crit Care.* 2012;27:745.e7-745.e12.
40. Schneider AG, Thorpe C, Dellbridge K, et al. Electronic bed weighing vs daily fluid balance changes after cardiac surgery. *J Crit Care.* 2013;28:1113.e1-1113.e5.
41. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report.* National Heart, Lung, and Blood Institute; 1998.
42. WHO Expert Committee. *Physical Status: The Use and Interpretation of Anthropometry.* WHO Technical Report Series 854. World Health Organization; 1995.
43. Sheehan P, Gonzalez C, Prado CM, et al. American Society for Parenteral and Enteral Nutrition clinical guidelines: the validity of body composition assessment in clinical populations. *JPEN J Parenter Enteral Nutr.* 2020;44(1):12-43.
44. Earthman CP. Body composition tools for assessment of adult malnutrition at the bedside: a tutorial on research considerations and clinical applications. *JPEN J Parenter Enteral Nutr.* 2015;39(7):787-822.
45. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care.* 1994;17(9):961-969.
46. Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. *J Trauma.* 1987;27(3):262-266.
47. Martindale RG, Patel JJ, Herron TJ, Codner PA. Sepsis and critical illness. In: Mueller CM, ed. *The ASPEN Adult Nutrition Support Core Curriculum.* 3rd ed. American Society for Parenteral and Enteral Nutrition; 2017:457-472.
48. Evans DC, Collier BR. Trauma, surgery, and burns. In: Mueller CM, ed. *The ASPEN Adult Nutrition Support Core Curriculum.* 3rd ed. American Society for Parenteral and Enteral Nutrition; 2017:473-488.
49. Haugen HA, Chan LN. Indirect calorimetry: a practical guide for clinicians. *Nutr Clin Pract.* 2007;22(4):377-388.
50. Academy of Nutrition and Dietetics. 2012 Critical illness evidence-based nutrition practice guideline. Evidence Analysis Library. 2012. Accessed January 31, 2021. [www.andeal.org/topic.cfm?menu=4800](http://www.andeal.org/topic.cfm?menu=4800)
51. Frankenfield D, Smith S, Cooney RN. Validation of 2 approaches to predicting resting metabolic rate in critically ill patients. *JPEN J Parenter Enteral Nutr.* 2004;28(4):259-264.
52. Frankenfield D. Validation of an equation for resting metabolic rate in older obese critically ill patients. *JPEN J Parenter Enteral Nutr.* 2011;35(2):264-269.
53. Mogensen, KM, Andrew BY, Corona JC, Robinson MK. Validation of the Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition recommendations for caloric provision to critically ill patients: a pilot study. *JPEN J Parenter Enteral Nutr.* 2016;40(5):713-721.
54. Compher C, Nicolo M, Chittams J, et al. Clinical outcomes in critically ill patients associated with the use of complex vs weight-only predictive equations. *JPEN J Parenter Enteral Nutr.* 2015;39(7):864-869.
55. Harris JA, Benedict FG. *Biometric Studies of Basal Metabolism in Man.* Carnegie Institution of Washington; 1919.
56. Mifflin MD, St. Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. *Am J Clin Nutr.* 1990;51(2):241-247.
57. Frankenfield DC, Roth-Yousey L, Compher C. Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese individuals, a systematic review. *J Am Diet Assoc.* 2005;105(5):775-789.
58. Institute of Medicine. *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.* National Academies Press; 2005:589.
59. ASPEN Board of Directors and Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. *JPEN J Parenter Enteral Nutr.* 2002;26(1 suppl):1SA-138SA.
60. Lentner C. *Geigy Scientific Tables: Units of Measurement, Body Fluids, Composition of the Body, Nutrition.* Vol 1. 8th ed. Ciba-Geigy Corporation; 1981.
61. Heimburger DC. Malnutrition and nutrition assessment. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. *Harrison's Principles of Internal Medicine.* 17th ed. McGraw-Hill; 2008:451.
62. Hansen RD, Raja C, Allen BJ. Total body protein in chronic diseases and in aging. *Ann NY Acad Sci.* 2000;904:345-352.
63. Meesters RJ, Wolfe RR, Deutz NE. Application of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the analysis of stable isotope enrichments of phenylalanine and tyrosine. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2009; 877(1/2):43-49.
64. Tuvdendorj D, Chinkes DL, Zhang XJ, et al. Adult patients are more catabolic than children during acute phase after burn injury: a retrospective analysis on muscle protein kinetics. *Intensive Care Med.* 2011;37(8):1317-1322.
65. Empana JP, Jouven X, Canouï-Poitrine F, et al. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. *Arterioscler Thromb Vasc Biol.* 2010;30(10):2047-2052.
66. Baker JP, Detsky AS, Wesson DE, et al. Nutritional assessment: a comparison of clinical judgment and objective measures. *N Engl J Med.* 1982;306(16):969-973.

67. White JV, Guenter P, Jensen G, et al. Consensus statement of the Academy of Nutrition and Dietetics/ American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). *J Acad Nutr Diet*. 2012;112(5):730-738.
68. Mogensen KM, Malone A, Becker P, et al. Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition consensus malnutrition characteristics: usability and association with outcomes. *Nutr Clin Pract*. 2019;34(5):657-665.
69. Jensen GL, Cederholm T, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. *JPEN J Parenter Enteral Nutr*. 2019;43(1):32-40.
70. Keller H, de van der Schueren MAE, Jensen GL, et al. Global Leadership Initiative on Malnutrition (GLIM): guidance on validation of the operational criteria for diagnosis of protein-energy malnutrition in adults. *JPEN J Parenter Enteral Nutr*. 2020;44(6):992-1003.

SAMPLE  
Not for Print  
or Sale

# Index

Letters *b*, *f* and *t* after page number indicate box, figure, and table, respectively.

## A

- AAAs. *See* aromatic amino acids
- AAD. *See* antibiotic-associated diarrhea
- AANH. *See* artificially administered nutrition and hydration
- abundance, of intestinal microbiome, 225*b*
- Academy of Nutrition and Dietetics
- on cancer nutrition screening, 158
  - Code of Ethics of, 459, 460*b*–461*b*
  - on malnutrition documentation, 19
  - on nutrition screening, 3
  - on obesity diets, 179
- acid-base balance, 7
- AcipHex. *See* rabeprazole
- ACP. *See* advance care planning
- Actigall. *See* ursodeoxycholic acid
- acute-phase proteins, 18
- Acute Physiology and Chronic Health Evaluation II (APACHE II), 4, 5*b*
- acute renal insufficiency, 195
- adalimumab, 28*b*
- Addison disease, 94*b*
- adjustable gastric banding (AGB), 306, 308, 309, 310*f*; 311–314, 322*t*
- $\alpha$ 2-adrenergic receptor antagonist, 67*b*
- advance care planning (ACP), 452, 455*b*, 457, 465*b*
- aflatoxins, 149*t*
- AGB. *See* adjustable gastric banding
- alanine aminotransferase (ALT), 415*b*
- albumin
- as acute-phase protein, 18
  - HPEN and, 415*b*
- alcohol
- after bariatric surgery, 320
  - cancer and, 149*t*
  - esophageal cancer and, 163
  - liver disease from, 109
  - osteoporosis and, 123
  - pancreatitis and, 127
- alkaline phosphatase (ALP), 415*b*
- Alli. *See* orlistat
- allylic sulfides, 150*b*
- aloe vera, 434–435
- for IBD, 443*b*
  - for IBS, 83*t*, 84
- alopecia areata, 94*b*
- ALP. *See* alkaline phosphatase
- alpha-gal syndrome, 209
- ALT. *See* alanine aminotransferase
- AMA. *See* American Medical Association
- amenorrhea, 199*b*
- American Medical Association (AMA)
- on EOL, 465, 466*b*
  - on informed consent, 458*b*
- American Society for Parenteral and Enteral Nutrition (ASPEN)
- on AANH, 455, 464, 464*b*–465*b*
  - on cancer nutrition screening, 158
  - on critically ill patients, 16–17
  - on gastrostomy, 462–463, 462*b*, 463*f*
  - on HPEN shortages, 417*b*
  - on malnutrition documentation, 19
  - on nutrition screening, 3
  - on protein requirements, 18
  - on Tralement, 416, 416*t*
- amino acids. *See also* branched-chain amino acid
- AAAs, 121–122
  - pancreas and, 126
  - in pediatric PN, 386*t*
  - in PN, 366, 366*t*
- amoxicillin and clavulanic acid (Augmentin)
- for pediatric dysmotility, 144
  - for SBS, 67*b*
- amylase-trypsin inhibitors (ATIs), 80
- AN. *See* anorexia nervosa
- anal fissures
- flexible sigmoidoscopy for, 30
  - pediatric constipation and, 145
- anaphylaxis, 208–209, 209*b*
- Andrographis paniculata (HMPL-004), 443*b*
- anemia
- eating disorders and, 192*b*, 199*b*
  - gastric surgery and, 295, 297*b*
  - with IBD, 46–47
  - iron deficiency, 94*b*
- anorectal motility study, 35–36
- anorexia, 186
- from antineoplastic therapy, 156*b*
  - esophageal cancer and, 163
- anorexia nervosa (AN), 185
- diagnostic criteria for, 187*b*
  - pediatric PN and, 385*b*



severity of, 186*t*  
 antacids, 422, 423*b*  
 anthocyanins, 150*b*  
 anthropometric measurements, 9–12  
   for liver disease, 112*b*  
   pediatric neurologic impairments and, 142  
 antibiotic-associated diarrhea (AAD), 270–271  
 antibiotics  
   IBD and, 43*t*  
   pancreatitis and, 127  
   for pediatric dysmotility, 144  
   for SBS, 67*b*, 69  
 anti-diarrheals  
   drug-nutrient interactions with, 423, 423*b*  
   PEI and, 130  
   for SBS, 66*b*, 68  
 antidumping diet, 205*b*, 293  
 antiemetics, 426, 426*b*  
 antiepileptics, 201  
 antigen-presenting cells (APCs), 92  
 antihistamines  
   drug-nutrient interactions of, 426  
   for food allergies, 212  
 anti-inflammatory agents, 429, 429*b*  
 anti-inflammatory diet for IBD (IBD-AID), 51*b*–52*b*  
 antineoplastic therapy, 155–156, 156*b*–158*b*  
 antioxidants  
   for pancreatitis, 129  
   prebiotics and, 260  
 $\alpha$ 1-antitrypsin prototype S/Z, 28*b*  
 anxiety  
   with eating disorders, 190  
   with gastric cancer, 165  
   with IBS, 84  
 APACHE II. *See* Acute Physiology and Chronic Health Evaluation II  
 APCs. *See* antigen-presenting cells  
 arachidonic acid, 383*b*  
 ARFID. *See* avoidant/restrictive food intake disorder  
 arginine  
   in EN, 344*b*  
   for pancreatitis, 129  
 aromatic amino acids (AAAs), 121–122  
 Artemisia absinthium (wormwood), 444*b*  
 artichoke leaf, 83*t*, 84  
 artificially administered nutrition and hydration (AANH). *See also specific topics*  
   ASPEN on, 455, 464, 464*b*–465*b*  
   ethics and legal issues of, 452–471, 453*b*–462*b*, 463*f*, 464*b*–470*b*  
 ascorbic acid. *See* vitamin C  
 aspartate aminotransferase (AST), 415*b*  
 ASPEN. *See* American Society for Parenteral and Enteral Nutrition  
 AST. *See* aspartate aminotransferase  
 asthma, 215  
 asymptomatic liver disease, 110  
 ATIs. *See* amylase-trypsin inhibitors

Atkins, Robert, 177  
 atopic eczema, 230  
 atypical anorexia nervosa, 189*b*  
 Augmentin. *See* amoxicillin and clavulanic acid  
 autoimmune cholangitis, 94*b*  
 autoimmune hepatitis, 94*b*, 95  
 autoimmune liver disease panel, 28*b*  
 autonomy, 453*b*, 455  
 avoidant/restrictive food intake disorder (ARFID), 185, 188, 188*b*  
 azathioprine, 46  
 azithromycin, 137  
 aztreonam, 137

## B

balloon expulsion test, 35–36  
 bariatric surgery, 305–330  
   diet after, 319–324, 322*t*, 323*t*  
   estimating weight loss from, 306*b*  
   macronutrients after, 319–320  
   micronutrients after, 320–324, 322*t*, 323*t*, 325*t*–326*t*  
   nutrition management before, 308  
   outpatient monitoring for, 324–329, 327*b*, 328*b*  
   patient screening for, 307, 307*b*  
   postoperative diet with, 311, 312*b*–313*b*  
   pregnancy after, 328–329  
   types of, 308–311, 310*f*  
 Barrett esophagus  
   eating disorders and, 196  
   esophageal cancer and, 163  
 basal energy expenditure (BEE), 17, 17*b*  
 BCAA. *See* branched-chain amino acid  
 BED. *See* binge eating disorder  
 BEE. *See* basal energy expenditure  
 beneficence, 453*b*, 455  
 berberine, 83*t*, 84  
 BIA. *See* bioelectrical impedance analysis  
 bicarbonate  
   in antacids, 423*b*  
   HPEN and, 415*b*  
   pancreas and, 126  
   for SBS, 64*t*  
 bile acids  
   intestinal microbiome and, 228*b*  
   obesity and, 175  
   SBS and, 67*b*, 68  
 bile salts, 60, 61, 62  
 biliopancreatic diversion with duodenal switch (BPD/DS), 306, 310, 310*f*  
   management of, 318  
   micronutrients after, 323*t*  
 Billroth I procedure (gastroduodenostomy), 293, 294*f*  
 Billroth II procedure. *See* gastrojejunostomy  
 binge eating disorder (BED), 185, 187  
   diagnostic criteria for, 187*b*  
   severity of, 186*t*

biochemical tests, 7–9, 7*t*–9*t*  
 bioelectrical impedance analysis (BIA)  
     for body composition, 12  
     for liver disease, 112*b*  
 bioethics committee, 453*b*  
 biotin (vitamin B7)  
     malabsorption and, 8*t*  
     in PN, 369*t*  
 bisacodyl, 145  
 bisphosphonates, 123  
 Bland, Anne, 455*b*  
 blenderized formulas  
     for HPEN, 405–406  
     for pediatric EN, 383  
 $\beta$ -blockers, 113  
 blood urea nitrogen (BUN)  
     for chronic kidney disease, 260  
     for eating disorders, 192*b*  
     HPEN and, 415*b*  
     PN and, 363*t*  
 BMI. *See* body mass index  
 BN. *See* bulimia nervosa  
 body composition  
     as anthropometric measurement, 12  
     for liver disease, 112*b*  
 body mass index (BMI). *See also* obesity  
     in AN, 186  
     as anthropometric measurement, 10, 11, 11*t*  
     CF and, 136  
     eating disorders and, 199–200  
     in malnutrition documentation, 22, 22*b*, 23*b*  
     in NRS-2002, 5*b*  
     pediatric neurologic impairments and, 142  
 body weight, 10–11  
     for liver disease, 112*b*  
 bone health/disease  
     celiac disease and, 94*b*, 95  
     IBD and, 46  
     intestinal microbiome and, 228*b*  
     liver disease and, 123  
     pediatric neurologic impairments and, 142  
*Boswellia serrata*, 437–438  
 bowel obstruction  
     flexible sigmoidoscopy for, 30  
     HPEN and, 410*b*  
     with RYGB, 317  
 BPD/DS. *See* biliopancreatic diversion with duodenal switch  
 bradycardia, 198*b*  
 brain death, 459*b*  
 branched-chain amino acid (BCAA)  
     intestinal microbiome and, 232  
     for liver disease, 117*b*, 121–122  
     MSUD and, 141  
 Bravo pH capsule, 32–33  
*Breathe* (Bland), 455*b*  
 bronchopulmonary aspiration, with EN, 333, 352

budesonide, 140  
 bulimia nervosa (BN), 185, 186–187  
     diagnostic criteria for, 187*b*  
     severity of, 186*t*  
 bulimia nervosa/binge eating disorder, 189*b*  
 bulk-forming laxatives, 424, 425*b*  
 BUN. *See* blood urea nitrogen

## C

CACS. *See* cancer anorexia-cachexia syndrome  
 calcium  
     after AGB, 322*t*  
     after bariatric surgery, 325*t*  
     after BPD/DW, 323*t*  
     celiac disease and, 101, 102*b*  
     for CRC, 166–167  
     eating disorders and, 194  
     in EN infant formulas, 382  
     gastric surgery and, 295, 297*b*  
     HPEN and, 415*b*  
     IBD and, 45, 47*t*  
     for osteoporosis, 123  
     pediatric neurologic impairments and, 142, 143  
     in PN, 363*t*, 367, 368*t*  
     after RYGB, 323*t*  
     after SG, 322*t*  
 calcium citrate  
     after bariatric surgery, 324  
     for SBS, 64*t*  
 calprotectin, 29*b*  
 CAM. *See* complementary and alternative medicine  
 cancer, 148–167, 148*t*. *See also specific types*  
     antineoplastic therapy for, 155–156, 156*b*–158*b*  
     associated factors with, 149*b*  
     nutrition screening, assessment, and intervention for, 158–159  
     obesity and, 305*b*  
     prevention of, 150, 150*b*–153*b*  
     selected interventions for, 160–162  
     weight loss and, 154–155  
 cancer anorexia-cachexia syndrome (CACS), 154–155  
*Cannabis sativa* (marijuana), 438–439  
 capsaicin, 151*b*  
 carbamazepine, 142  
 carbohydrate. *See also* fermentable oligosaccharides, disaccharides, monosaccharides, and polyols  
     alpha-gal syndrome and, 209  
     after bariatric surgery, 319  
     celiac disease and, 102*b*  
     in EN, 340, 341*b*–345*b*  
     IBD and, 43  
     IBS and, 80  
     liver disease and, 119*b*  
     obesity diet and, 177–178

- pancreas and, 126
- pancreatitis and, 129*b*, 130
- in pediatric PN, 387–388
- refeeding syndrome and, 201
- SBS and, 61
- cardiac arrhythmias, eating disorders and, 195, 198*b*
- carnitine
  - HPEN and, 415*b*
  - pediatric neurologic impairments and, 142
- β--carotene, 151*b*
- catechin, 151*b*
- cathartic colon, 196
- CBT. *See* cognitive behavioral therapy
- CDED. *See* Crohn's disease exclusion diet
- CDI. *See* Clostridioides difficile infection
- celiac disease
  - clinical manifestations of, 92–93, 94*b*
  - constipation and, 145
  - diagnosis of, 96–98, 97*t*
  - epidemiology of, 91–92
  - gastrointestinal tests for, 27*b*
  - IBD and, 29*b*
  - IBS and, 80
  - intestinal microbiome and, 230
  - pathogenesis of, 92, 93*f*
  - PEI and, 130
  - push enteroscopy for, 33
  - treatment of, 98–104, 102*b*, 103*f*
  - wireless capsule endoscopy for, 31
- cerebral palsy, 141
- CF. *See* cystic fibrosis
- CFTR. *See* cystic fibrosis transmembrane conductance regulator gene
- cheilosis, 196
- chemotherapy
  - malnutrition from, 156*b*
  - PEG with, 36
- children. *See* pediatrics
- chloride, 415*b*
- cholecystokinin, 127
- cholelithiasis, 305*b*
- cholera, 68
- cholestasis, 372*b*
- cholestyramine
  - drug-nutrient interactions of, 429, 430*b*
  - IBD and, 45
  - for SBS, 67*b*
- choline, 8*t*
- Christianity, on EOL, 467*b*
- chromium
  - malabsorption and, 8*t*
  - in PN, 369*t*
  - for SBS, 64*t*
- chronic intestinal pseudo-obstruction, 144
- chronic kidney disease, 260
- chylothorax, 385*b*
- ciguatera poisoning, 209–210
- cimetidine (Tagamet), 66*b*
- ciprofloxacin (Cipro)
  - for pediatric dysmotility, 144
  - for SBS, 67*b*
- cirrhosis, 110–111
  - CF and, 137
  - esophageal varices with, 113, 121
  - hyponatremia and, 111, 112
  - liver transplantation for, 113
- CLE. *See* confocal laser endomicroscopy
- client history, 14, 15*b*
- Clinolipid, 406, 406*t*, 407*t*
- clonidine, 67*b*, 68
- Clostridioides difficile infection (CDI)
  - AAD from, 270
  - gastrointestinal microbiome and, 226
  - probiotics for, 271–272
- CMPA. *See* cow's milk protein allergy
- cobalamin. *See* vitamin B12
- codeine phosphate, 66*b*
- cognitive behavioral therapy (CBT)
  - for eating disorders, 202
  - for obesity, 176
- colesevelam, 430, 430*b*
- colestipol
  - drug-nutrient interactions of, 429, 430*b*
  - for SBS, 67*b*
- collagenous colitis, 437–438
- colonoscopy, 30
- colonostomy, 298, 299*b*
- colorectal cancer (CRC), 148*t*, 149*b*, 166–167
  - colonoscopy for, 30
  - IBS and, 74
  - intestinal microbiome and, 230
- colorectal polyps, 30
- commensal microorganisms, 225*b*
- competence, vs. decisional capacity, 458*b*
- complementary and alternative medicine (CAM). *See also* nutraceutical supplements
  - for IBS, 82–85, 83*t*
- composition
  - of bioethics committee, 453*b*
  - of intestinal microbiome, 225*b*
- computed tomography (CT), 7–9
  - for body composition, 12
  - for liver disease, 112*b*
- confocal laser endomicroscopy (CLE), 76
- congenital heart disease, 385*b*
- connective tissue disorders, 139
- constipation
  - anorectal motility study for, 35
  - from antineoplastic therapy, 156*b*
  - cancer and, 158
  - CF and, 136, 137
  - eating disorders and, 195–196, 198*b*

- with EN, 352, 353*b*
  - gastric emptying studies for, 36
  - with HPEN, 413*b*
  - inborn errors of metabolism and, 140
  - pediatric neurologic impairments and, 141, 142, 143
  - in pediatrics, 145
  - prebiotics and, 258*b*, 260
  - with SG, 315
  - Contrave. *See* naltrexone and bupropion
  - The Conversation Project, 455*b*
  - copper
    - after AGB, 322*t*
    - after bariatric surgery, 325*t*
    - after BPD/DW, 323*t*
    - celiac disease and, 101
    - malabsorption and, 9*t*
    - in PN, 369*t*
    - after RYGB, 323*t*
    - for SBS, 64*t*
    - after SG, 322*t*
    - surgery and, 288
  - coronary artery disease, obesity and, 305*b*
  - corticosteroids
    - for EoE, 140
    - IBD and, 45
  - coumarin, 151*b*
  - COVID-19
    - ethics with, 469–471
    - turmeric for, 438
  - cow's milk
    - in EN infant formulas, 380
    - food allergies to, 207–208
    - intestinal microbiome and, 238*b*, 240, 245*b*
  - cow's milk protein allergy (CMPA), 137–138
  - COX. *See* cyclooxygenase
  - CRC. *See* colorectal cancer
  - C-reactive protein (CRP), 18
    - IBD and, 29*b*
    - prebiotics and, 259, 260
  - Creon, 426
  - critically ill patients, 14–17, 15*b*, 16*b*
    - EN timing for, 340
  - Crohn's disease
    - Boswellia serrata* for, 437
    - clinical presentation of, 44
    - colorectal cancer and, 166
    - delayed puberty with, 46
    - EoE and, 139
    - fish oils for, 440
    - growth impairment with, 45–46
    - marijuana for, 439
    - prebiotics for, 267, 273–274
    - wireless capsule endoscopy for, 31
  - Crohn's disease exclusion diet (CDED), 52*b*–53*b*
  - CRP. *See* C-reactive protein
  - Cruzan, Nancy Beth, 456*b*–457*b*
  - CT. *See* computed tomography
  - cue-based patient and family discussion, 453*b*
  - curcumin. *See* turmeric
  - cyclooxygenase (COX), 440
  - cynarin, 151*b*
  - cystic fibrosis (CF)
    - clinical presentation and diagnosis of, 136
    - CMPA and, 137–138
    - complications of, 137
    - constipation and, 145
    - EoE and, 139–140
    - FPIES and, 138–139
    - pancreatic enzyme for, 132
    - pediatric PN and, 385*b*
    - in pediatrics, 135–137
    - PEI and, 130
    - treatment and nutrition management for, 136–137
  - cystic fibrosis transmembrane conductance regulator gene (*CFTR*), 135, 136
- ## D
- dairy. *See* cow's milk
  - DASH. *See* Dietary Approaches to Stop Hypertension
  - death, legal definition of, 459*b*
  - decisional capacity, 453*b*
    - vs.* competence, 458*b*
  - decompensated cirrhosis. *See* cirrhosis
  - dental enamel erosion, 196, 199*b*
  - depression
    - with gastric cancer, 165
    - with IBS, 84
    - obesity and, 305*b*
  - dermatitis, 215
  - dermatitis herpetiformis, 94, 94*b*
  - dexamethasone, 155
  - dexlansoprazole (Dexilant), 66*b*
  - dextrose
    - in pediatric PN, 386*t*, 387–388
    - in PN, 367, 367*b*
  - DGA. *See* Dietary Guidelines for Americans
  - DHA. *See* docosahexaenoic acid
  - diabetes mellitus. *See also* type 1 diabetes mellitus; type 2 diabetes mellitus
    - AAD, 270–271
    - colorectal cancer and, 166
    - pancreatic cancer and, 165
  - dialectical behavior therapy, 202
  - dialysis
    - liver disease and, 117*b*
    - pediatric PN and, 385*b*, 390, 391*b*
  - diaphragmatic hernia, 385*b*
  - diarrhea
    - from antineoplastic therapy, 157*b*

- with EN, 332, 352, 352*b*
  - gastric emptying studies for, 36
  - with HPEN, 413*b*
  - inborn errors of metabolism and, 140
  - probiotics for, 270–273
  - push enteroscopy for, 33
  - radiation-induced, 272–273
  - with RYGB, 316
  - SBS and, 61
  - diarrhea-predominant IBS (IBS-D), 77
  - diet. *See also* specific types and topics
    - after AGB, 319–324, 322*t*, 323*t*
    - esophageal cancer and, 163
    - for IBD, 49–54, 50*b*–53*bb*
    - for IBS, 76–81
    - intestinal microbiome and, 232–244, 238*b*
    - for obesity, 177–179
    - for pediatric constipation, 145
    - prebiotics in, 256–257
    - for SBS, 62, 63*t*
  - Dietary Approaches to Stop Hypertension (DASH), 178
  - dietary fiber. *See* fiber
  - Dietary Guidelines for Americans (DGA), 178, 179
  - Dietary Supplement Health and Education Act of 1994, 266
  - diet history, 5–6
  - digestants, 426
  - DIOS. *See* distal intestinal obstruction syndrome
  - diphenoxylate with atropine (Lomotil)
    - drug-nutrient interactions of, 423, 423*b*
    - for SBS, 66*b*
  - disaccharidase activity panel, 28*b*
  - distal intestinal obstruction syndrome (DIOS), 137
  - diuretics
    - AN and, 186
    - BN and, 187*b*
    - hyponatremia and, 122
    - pancreatitis and, 127
    - after surgery, 286
  - diversity, of intestinal microbiome, 225*b*, 230
  - diverticulitis, 30
  - d-limonene, 152*b*
  - docosahexaenoic acid (DHA)
    - in EN infant formulas, 383*b*
    - in fish oils, 440
  - double-balloon enteroscopy, 34
  - Down syndrome, 94*b*
  - doxycycline, 67*b*
  - dronabinol, 155
  - drug-nutrient interactions, 422–431
    - with antacids, 422, 423*b*
    - with antidiarrheals, 423, 423*b*
    - of antiemetics, 426, 426*b*
    - of anti-inflammatory agents, 429, 429*b*
    - with digestants, 426
    - of H<sub>2</sub> receptor antagonists, 426–428, 427*b*
    - of lipid-regulating drugs, 429–430, 430*b*
    - of orlistat, 430, 431*b*
    - with pancreatic enzymes, 426
    - of PPIs, 426–428, 427*b*
    - of prokinetic agents, 428–429, 428*b*
    - of protectants, 426–428, 427*b*
    - of teduglutide, 430–431, 431*b*
  - dual-energy x-ray absorptiometry (DXA)
    - for body composition, 12
    - for celiac disease, 95
    - for eating disorders, 192*b*
    - for liver disease, 112*b*
  - dumping syndrome
    - esophagectomy and, 291, 292*b*
    - with RYGB, 316
    - with SG, 315
  - DXA. *See* dual-energy x-ray absorptiometry
  - dysbiosis, of intestinal microbiome, 225*b*, 230
  - dyslipidemia
    - obesity and, 305*b*
    - prebiotics and, 258*b*
  - dysmotility. *See* motility/dysmotility
  - dyspepsia
    - peppermint oil for, 439
    - prebiotics and, 260
  - dysphagia
    - with AGB, 312–313, 314
    - from antineoplastic therapy, 157*b*
    - eating disorders and, 196
    - EoE and, 139, 215
    - esophageal cancer and, 163
    - esophageal motility study for, 35
    - pediatric neurologic impairments and, 141, 143
    - PEG for, 36
  - dysphoria, 187
  - dysplasia, eating disorders and, 196
- ## E
- early dumping syndrome
    - with RYGB, 316
    - with SG, 315
  - eating disorders, 185–204. *See also* specific types
    - with AGB, 314
    - clinical presentation and diagnosis of, 191–192, 191*b*, 192*b*
    - complications of, 192–197, 198*b*–199*b*
    - follow-up monitoring for, 202–203, 203*b*–204*b*
    - obesity and, 305*b*
    - pathogenesis of, 189–191
    - pharmacotherapy for, 201
    - prevalence of, 190–191
    - refeeding syndrome and, 201
    - severity of, 186*t*
    - treatment of, 197–202
  - eggs

- EoE and, 139, 216
- food allergies to, 207
- pediatric PN and, 385b
- eicosapentaenoic acid (EPA)
  - for CACS, 155
  - in fish oils, 440
- electrocardiogram, 192b
- electrolytes
  - antidiarrheals and, 423
  - eating disorders and, 193
  - EN and, 333
  - with HPEN, 413b
  - HPEN and, 415b
  - liver disease and, 123
  - in pediatric PN, 388
  - in PN, 367, 368t
  - profile for, 7
  - SBS and, 62
- electromyography (EMG), 35
- elxacaftor, 137
- elimination diet, 211b
- ellagic acid, 151b
- EMG. *See* electromyography
- EN. *See* enteral nutrition
- encopresis, 145
- end-of-life (EOL)
  - AMA on, 465, 466b
  - ethics and legal issues of, 456–457, 456b–457b
  - religion on, 465, 467b–468b
- endoscopic retrograde cholangiopancreatography (ERCP), 34
- endoscopy
  - for celiac disease, 97–98
  - for EoE, 139
  - for obesity therapy, 329
- energy
  - for cancer, 159
  - intestinal microbiome and, 229f
  - liver disease and, 118b
  - obesity and, 175
  - pancreatitis and, 130
  - pediatric neurologic impairments and, 143
  - in pediatric PN, 387
  - surgery and, 285, 285t
- Enhanced Recovery After Surgery (ERAS), 284
- enteral nutrition (EN). *See also* home parenteral and enteral nutrition
  - for ARFID, 188
  - bronchopulmonary aspiration with, 333, 352
  - for cancer, 161–162
  - for CF, 137
  - complications of, 333
  - contraindications for, 332–333
  - delivery of, 346b–352b, 347–351
  - diarrhea with, 332, 352, 352b
  - ethics and legal issues of, 455
  - fatty acids with, 357b
  - feeding protocols for, 358
  - food/nutrition-related history for, 6
  - formula selection for, 340–347, 341b–345b
  - for hepatic encephalopathy, 122
  - hyperglycemia with, 356b
  - hyponatremia with, 356b
  - hyperphosphatemia with, 357b
  - hypoglycemia with, 356b
  - for IBD, 48–49
  - indications for, 332
  - for liver disease, 114, 115b–117b
  - malabsorption with, 352, 355b
  - modular products for, 346
  - monitoring of, 352–358, 353b–357b
  - motility with, 352, 355b
  - nausea and vomiting with, 352, 354b
  - osmolality of, 346
  - for pancreatitis, 128, 128b
  - for pediatric dysmotility, 144
  - for pediatric neurologic impairments, 143
  - pediatric PN and, 393
  - in pediatrics, 374–384, 375b, 377t, 378b, 380b, 381b, 383b
  - PN and, 362
  - refeeding syndrome with, 357b
  - timing of, 339
  - tube type and site for, 333–337, 334b–339b
- enteroscopy, 33–34
- enterotype grouping, of intestinal microbiome, 225b, 226
- Enzadyne, 426
- EoE. *See* eosinophilic esophagitis
- EOL. *See* end-of-life
- eosinophilic esophagitis (EoE), 215–216
  - CF and, 139–140
- EPA. *See* eicosapentaenoic acid
- epilepsy, 94b
- epinephrine, 212
- ERAS. *See* Enhanced Recovery After Surgery
- ERCP. *See* endoscopic retrograde cholangiopancreatography
- erythromycin
  - drug-nutrient interactions of, 428b
  - for pediatric dysmotility, 144
- esomeprazole (Nexium), 66b
- esophageal cancer, 148t, 149b, 163
- esophageal motility study, 35
- esophageal obstruction, 36
- esophageal varices, 113, 121
- esophagectomy, 291–292, 291f, 292b, 292f, 293f
- esophagitis. *See also* eosinophilic esophagitis
  - eating disorders and, 196
- ESPEN. *See* European Society for Clinical Nutrition and Metabolism
- ESPGHAN. *See* European Society for Paediatric Gastroenterology, Hepatology, and Nutrition
- estrogen, 192b
- ethics



of AANH, 452–471, 453*b*–462*b*, 463*f*, 464*b*–470*b*  
of Academy of Nutrition and Dietetics, 459, 460*b*–461*b*  
common questions on, 458*b*–459*b*  
with COVID-19, 469–471  
of EOL, 456–457, 456*b*–457*b*  
of gastrostomy, 462–463, 462*b*, 463*f*  
policies and procedures for, 468–469, 469*b*, 470*b*  
with QOL, 452  
ethics consults, 453*b*  
European Society for Clinical Nutrition and Metabolism (ESPEN)  
on CRC, 167  
on energy for cancer, 159  
European Society for Paediatric Gastroenterology, Hepatology,  
and Nutrition (ESPGHAN), 98  
euthyroid sick syndrome, 192*b*, 198*b*  
evidence-based medicine, 453*b*  
ezetimibe, 430*b*

## F

FAAN. *See* Food Allergy and Anaphylaxis Network  
familial polyposis syndromes  
colorectal cancer and, 166  
wireless capsule endoscopy for, 31  
family-based therapy (Maudsley method), 202  
famotidine (Pepcid)  
licorice root and, 436  
for SBS, 66*b*  
fat  
after bariatric surgery, 319  
celiac disease and, 102*b*  
for CF, 136–137  
in EN, 341*b*–345*b*, 346  
in EN infant formulas, 382  
gastric surgery and, 297*b*  
liver disease and, 119*b*  
pancreas and, 126  
pancreatitis and, 129*b*  
in pediatric PN, 387  
PEI and, 130–131  
fatty acids. *See also* omega; omega-3 fatty acids; polyunsaturated  
fatty acids; short-chain fatty acids  
with EN, 357*b*  
with HPEN, 414*b*  
pancreas and, 126  
SBS and, 60  
FDA. *See* Food and Drug Administration, U.S.  
fecal impaction, 145  
fecal incontinence, 35  
feeding tubes, 36–37. *See also specific types*  
fermentable oligosaccharides, disaccharides, monosaccharides,  
and polyols (FODMAPs)  
food intolerances for, 216–217  
IBD and, 50*b*–51*b*  
IBS and, 78–80, 79*f*

intestinal microbiome and, 241*b*, 243–244  
fermented foods, 265–266, 266*b*  
intestinal microbiome and, 233–234  
fiber  
after bariatric surgery, 320  
celiac disease and, 102*b*  
defined, 256  
in EN, 341*b*–345*b*, 345*b*  
for IBD, 53*b*  
for IBS, 80–81  
intestinal microbiome and, 229*f*, 230, 232–233  
for pediatric constipation, 145  
PEI and, 131  
*vs.* prebiotics, 255–256, 255*f*  
fish  
EoE and, 216  
food allergies to, 207, 209–210  
fish oils, 440  
in EN, 345*b*  
in PN, 118  
fistula, 32, 287  
HPEN and, 410*b*  
with IBD, 44  
zinc and, 48  
Five Wishes, 455*b*  
Flagyl. *See* metronidazole  
flatulence  
with fiber, 81  
with FODMAPs, 78, 217  
with lactose intolerance, 77  
with RYGB, 316  
with sucrose, 77  
flavonoids, 151*b*  
flexible sigmoidoscopy, 30–31  
fluid retention  
with HPEN, 414*b*  
with licorice root, 436  
with liver disease, 121  
fluids  
after bariatric surgery, 319  
in pediatric PN, 387, 390  
surgery and, 286  
fluticasone, 140  
FODMAPs. *See* fermentable oligosaccharides, disaccharides,  
monosaccharides, and polyols  
folate (vitamin B9)  
after AGB, 322*t*  
after bariatric surgery, 325*t*  
after BPD/DW, 323*t*  
celiac disease and, 93, 101, 102*b*  
eating disorders and, 194  
gastric surgery and, 295  
IBD and, 45, 46, 47*t*  
liver disease and, 120*b*  
malabsorption and, 8*t*

- pediatric neurologic impairments and, 142
- in PN, 369*t*
- after RYGB, 323*t*
- after SG, 322*t*
- surgery and, 287
- follicle-stimulating hormone, 192*b*
- follow-up formulas, 383
- Food Allergen Labeling Consumer Protection Act of 2004, 212
- food allergies, 207–216
  - anaphylaxis from, 208–209, 209*b*
  - diagnosis of, 210–212, 210*b*–211*b*
  - IBS and, 75–80
  - IgE and, 208–213, 210*b*–211*b*
  - management of, 212–213, 213*f*
  - prevalence of, 207–208
- Food Allergy and Anaphylaxis Network (FAAN), 209–210
- Food Allergy Safety, Treatment, Education, and Research Act of 2021, 212
- Food and Drug Administration, U.S. (FDA)
  - on endoscopic obesity therapy, 329
  - on HPEN shortages, 417*b*
  - on human milk for pediatric EN, 379
  - on Omegaven, 407
  - probiotics and, 266
- food intolerances, 216–217
- food/nutrition-related history, 5–6
- food protein-induced allergic proctocolitis (FPIAP), 215
- food protein-induced enterocolitis syndrome (FPIES), 214–215
  - CF and, 138–139
- food record/diary, 5–6
  - for obesity, 176
- forgoing life-sustaining treatment, 453*b*
- FPIAP. *See* food protein-induced allergic proctocolitis
- FPIES. *See* food protein-induced enterocolitis syndrome
- fructose, 78
- fruit juices, 145
- fruits, 238–239, 238*b*, 245*b*
- function, of intestinal microbiome, 225*b*, 227–230, 228*b*, 229*f*
- furosemide, 127

## G

- galactose- $\alpha$ 
  - alpha-gal syndrome and, 209
  - gastrointestinal tests for, 27*b*
- GALAD score, 28*b*
- gallstones
  - ERCP for, 34
  - obesity and, 174
- gastric cancer, 148*t*, 149*b*, 164
- gastric emptying
  - with AGB, 314
  - esophagectomy and, 291
  - gastric surgery and, 297*b*
  - SBS and, 61, 62

- SmartPill capsule for, 32
- studies, 36
- gastric outlet obstruction, 37
- gastric surgery, 293–295, 294*f*, 295*b*–297*b*
- gastrin, 126, 127
- gastroduodenostomy (Billroth I procedure), 293, 294*f*
- gastroesophageal reflux disease (GERD)
  - aloe vera for, 434
  - Bravo pH capsule for, 32
  - cancer and, 149*t*
  - EoE and, 139
  - esophageal motility study for, 35
  - gastric cancer and, 164
  - obesity and, 305*b*
  - pediatric neurologic impairments and, 141, 142, 143
  - with SG, 315
  - SL and, 315
- gastrointestinal disorders. *See also specific topics*
  - nutrition assessment for, 2–23
  - surgery for, 284–303, 290*f*
  - tests and procedures for, 27–38, 28*b*–29*b*
- gastrojejunal tube, 137
- gastrojejunostomy (Billroth II procedure), 293, 294*f*
  - for liver disease, 116*b*
  - RYGB and, 317
- gastroparesis
  - eating disorders and, 198*b*
  - gastric emptying studies for, 36
  - gastric surgery for, 293*b*
  - in pediatrics, 143
  - PEJ for, 37
  - peppermint oil for, 439
  - SmartPill capsule for, 32
- gastrostomy. *See also* percutaneous endoscopic gastrostomy
  - ASPEN on, 462–463, 462*b*, 463*f*
  - for CF, 137
  - esophagectomy and, 291
  - ethics of, 462–463, 462*b*, 463*f*
  - for liver disease, 115*b*–116*b*
  - for pediatric neurologic impairments, 143
- GATTEX. *See* teduglutide
- genistein, 152*b*
- GERD. *See* gastroesophageal reflux disease
- gestational diabetes mellitus, 305*b*
- GI bleeding
  - EN and, 333
  - push enteroscopy for, 33
  - wireless capsule endoscopy for, 31
- gingivitis, 196
- GIR. *See* glucose infusion rate
- GLP-2. *See* glucagon-like peptide-2 analogues
- glucagon, 126
- glucagon-like peptide-2 analogues (GLP-2), 67*b*, 69
- glucocorticoids, 212
- glucose. *See also* hyperglycemia; hypoglycemia
  - HPEN and, 415*b*



- pancreas and, 126
  - PN and, 363*t*
  - refeeding syndrome and, 201
  - glucose infusion rate (GIR)
    - in pediatric PN, 388
    - in PN, 367, 367*b*
  - glutamine
    - in EN, 344*b*
    - for IBD, 443*b*
    - for IBS, 83, 83*t*, 92
    - for pancreatitis, 129
  - glutathione, 260
  - gluten. *See also* celiac disease
    - IBS and, 80
  - gluten ataxia, 94
  - gluten-free diet
    - for celiac disease, 93, 101–104, 103*f*
    - for IBD, 51*b*
    - for IBS, 80
    - intestinal microbiome and, 241*b*, 244
    - nonadherence to, 103
  - gluten neuropathy, 95
  - glycogen storage disease, 141
  - Glycyrrhiza glabra* (licorice root), 436
  - grains. *See also* wheat
    - intestinal microbiome and, 238*b*, 239–240, 245*b*
  - growth impairment
    - with Crohn's disease, 45–46
    - from food allergies, 213
  - growth impairments, pediatric neurologic impairments and, 142
  - gut barrier, probiotics and, 268
- ## H
- H2 receptor antagonists
    - drug-nutrient interactions of, 426, 427*b*
    - licorice root and, 436
    - for SBS, 66*b*, 68
  - Harris-Benedict equation, 17, 17*b*
  - head and neck cancer
    - malnutrition with, 162
    - PEG for, 36
    - surgery for, 289
  - health literacy, 454*b*
  - Heineke-Mikulicz strictureplasty, 300, 300*f*
  - Helicobacter pylori*
    - breath test for, 28*b*
    - gastric cancer and, 164
    - licorice root for, 436
    - probiotics for, 273
  - hemorrhoids
    - flexible sigmoidoscopy for, 30
    - pediatric constipation and, 145
  - hemothorax, 372*b*
  - hepatic encephalopathy
    - cirrhosis and, 111
    - with liver disease, 121–122, 122*f*
  - hepatic steatosis, 372*b*
  - hepatic transport proteins, 18
  - hepatitis A, 113
  - hepatitis B, 110, 113
  - hepatitis C, 110
    - insulin resistance and hyperglycemia with, 123
    - licorice root for, 436
    - milk thistle for, 437
  - hepatocellular carcinoma
    - GALAD score and, 28*b*
    - liver disease and, 113
  - hepatorenal syndrome, 111
  - hereditary pancreatitis, 29*b*
  - herpes simplex virus, 438
  - hiatal hernia, 305*b*
  - Hirschsprung disease, 145
  - HIV. *See* human immunodeficiency virus
  - HLA-DQ
    - celiac disease and, 92, 96*t*, 97, 101
    - IBD and, 29*b*
    - NCGS and, 80
  - HMB. *See*  $\beta$ -hydroxy-beta-methylbutyrate
  - HMBANA. *See* Human Milk Banking Association of North America
  - HMPL-004. *See* *Andrographis paniculata*
  - home parenteral and enteral nutrition (HPEN), 400–420
    - care provider for, 400, 401*b*, 402*b*
    - complications of, 411, 411*b*–414*b*
    - discharge orders for, 404, 404*b*
    - financial reimbursement for, 407–408, 409*b*
    - formula selection for, 404
    - hospital discharge considerations for, 400–408, 401*b*–405*b*, 407*t*
    - initiation of, 408–409, 410*b*
    - monitoring of, 414*b*, 415–418, 415*b*, 416*b*, 416*t*, 417*b*
    - nonadherence to, 419, 419*b*
    - predischarge and postdischarge education for, 401–404, 405*b*
    - QOL with, 418, 418*b*
    - refeeding syndrome with, 410–411, 413*b*, 414*b*
    - shortages in, 417, 417*b*
    - support device for, 400–402
    - Tralement for, 416, 416*t*
    - transitioning off, 418–419
  - human immunodeficiency virus (HIV)
    - milk thistle for, 437
    - turmeric for, 438
  - human leukocyte antigen. *See* HLA-DQ
  - human milk
    - for CF, 136–137
    - in EN infant formulas, 383*b*
    - gastrointestinal microbiome and, 227
    - in pediatric EN, 376–379, 378*b*

prebiotics and, 258  
 Human Milk Banking Association of North America (HMBANA), 379  
 β-hydroxy-beta-methylbutyrate (HMB), 155  
 hyperaldosteronemia, 196, 199b  
 hyperammonemia, 390  
 hyperamylasemia, 198b  
 hypereosinophilic syndrome, 139  
 hyperglycemia  
   with EN, 356b  
   with HPEN, 413b  
   with liver disease, 123  
   with pediatric PN and, 390–391  
   with PN, 372b  
 hyperlipidemia  
   eating disorders and, 198b  
   obesity and, 307t  
   waist circumference and, 12  
 hypermagnesemia, 193, 195–196  
 hypernatremia  
   with EN, 356b  
   with licorice root, 436  
 hyperphosphatemia, 357b  
 hypertension. *See also* portal hypertension  
   alcohol-related liver disease and, 109  
   CF and, 137  
   obesity and, 305b, 307t  
   waist circumference and, 12  
 hypertriglyceridemia  
   with pediatric PN, 392, 392t  
   with PN, 372b  
 hypochloremia, 198b  
 hypoglycemia  
   eating disorders and, 198b  
   with EN, 356b  
   with HPEN, 413b  
   MSUD and, 141  
   with PN, 372b  
 hypokalemia  
   eating disorders and, 199b  
   with HPEN, 414b  
   with licorice root, 436  
 hypomagnesemia  
   eating disorders and, 193  
   with HPEN, 414b  
 hyponatremia  
   cirrhosis and, 111, 112  
   eating disorders and, 193  
 hypophosphatemia  
   eating disorders and, 193, 198b  
   with HPEN, 414b  
 hypothyroidism  
   constipation and, 145  
   obesity and, 175  
 hypoventilation syndrome, 305b  
 hypovolemia, 193

**I**  
 IBD. *See* inflammatory bowel disease  
 IBD-AID. *See* anti-inflammatory diet for IBD  
 Iberogast. *See* STW 5  
 IBS. *See* irritable bowel syndrome  
 IBS-D. *See* diarrhea-predominant IBS  
 ibuprofen, 137  
 ideal body weight (IBW), 10  
   protein and, 18  
 idiopathic dilated cardiomyopathy, 94b  
 IgA. *See* immunoglobulin A  
 IgE. *See* immunoglobulin E  
 IgG. *See* immunoglobulin G  
 IL-6. *See* interleukin-6  
 ILE. *See* intravenous lipid emulsion  
 ileostomy, 298, 299b  
 immune system  
   intestinal microbiome and, 228, 228b  
   prebiotics and, 258b, 259  
   probiotics and, 268–269  
 immunoglobulin A (IgA), 94b, 96–97, 96t  
 immunoglobulin E (IgE)  
   food allergies and, 208–213, 210b–211b  
   IBS and, 76  
 immunoglobulin G (IgG)  
   celiac disease and, 97  
   for food allergies, 211b  
 immunomodulating diets, 129  
 immunotherapy, 156b  
 Imodium. *See* loperamide  
 inborn errors of metabolism, 140–141  
   EN infant formulas for, 382  
 Indigo naturalis (Qing-Dai), 445b  
 indoles, cancer prevention from, 152b  
 infant formulas, 379–383, 380b, 381b, 383b  
 infertility  
   eating disorders and, 199b  
   obesity and, 305b  
 inflammatory bowel disease (IBD), 42–55. *See also* Crohn's disease; ulcerative colitis  
   anemia with, 46–47  
   bone health and, 46  
   clinical presentation of, 44  
   colonoscopy for, 30  
   diets for, 49–54, 50b–53bb  
   EN for, 48–49  
   flexible sigmoidoscopy for, 30  
   IBS and, 74  
   intestinal microbiome and, 228, 230  
   malabsorption and, 45  
   malnutrition and, 44–46  
   marijuana for, 439  
   nutraceutical supplements for, 433, 442, 443b–445b  
   nutrition management of, 44–48, 46t  
   pathogenesis of, 42–43, 43t

- pediatric PN and, 385*b*
  - PN for, 49
  - polyphenols for, 437
  - probiotics for, 273–275
  - tests for, 28*b*–29*b*
  - turmeric for, 438
  - infliximab, 28*b*
  - influenza, 437
    - vaccination for, 259
  - informed consent, 458*b*
  - INR. *See* international normalized ratio
  - Institute for Healthcare Improvement, 455*b*
  - insulin
    - pancreas and, 126, 127
    - refeeding syndrome and, 201
  - insulin-like growth factor 1, 127
  - insulin resistance
    - colorectal cancer and, 166
    - with liver disease, 123
    - pancreatic cancer and, 165
  - interleukin-1 $\beta$ , 259
  - interleukin-6 (IL-6), 4, 5*b*
  - internal hernia, 317
  - international normalized ratio (INR)
    - cirrhosis and, 110
    - HPEN and, 415*b*
    - vitamin K and, 429
  - intestinal lengthening, for SBS, 301, 302*f*
  - intestinal microbiome, 224–247, 225*b*. *See also* prebiotics; probiotics
    - cow's milk and, 238*b*, 240, 245*b*
    - development of, 227
    - diet and, 232–244, 238*b*
    - dietary recommendations for, 244–247, 244*b*
    - digestion and absorption by, 230–231, 231*f*
    - diversity of, 225*b*, 230
    - dysbiosis of, 225*b*, 230
    - fermented foods and, 233–234
    - fiber and, 229*f*, 232–233
    - FODMAPs and, 241*b*, 243–244
    - fruits and, 238–239, 238*b*, 245*b*
    - function of, 225*b*, 227–230, 228*b*, 229*f*
    - gluten-free diet and, 241*b*, 244
    - grains and, 238*b*, 239–240, 245*b*
    - ketogenic diet and, 241*b*, 243
    - legumes and, 238*b*, 239–240
    - measurement of, 226–227
    - Mediterranean diet and, 241*b*, 242
    - microbial metabolites of, 229–230, 229*f*
    - nuts and, 237–238, 238*b*
    - pattern-based diets for, 241–244
    - polyunsaturated fats and, 245*b*
    - protein and, 245*b*
    - synbiotics and, 233–234
    - taxonomy of, 225–226, 226*f*
    - vegan diet and, 241*b*, 242–243
    - vegetables and, 238–239, 238*b*, 245*b*
    - vegetarian diet and, 241*b*, 242–243
    - Western-style diet and, 241*b*, 242
  - Intralipid, 405, 406*t*
  - intravenous lipid emulsion (ILE)
    - for HPEN, 406–407, 407*t*
    - for liver disease, 118
    - in PN, 364*b*
  - iodine, 9*t*
  - iron
    - after AGB, 322*t*
    - for anemia, 46
    - after bariatric surgery, 324, 325*t*
    - after BPD/DW, 323*t*
    - celiac disease and, 93, 101, 102*b*
    - CF and, 136
    - eating disorders and, 194
    - gastric surgery and, 295, 297*b*
    - HPEN and, 415*b*
    - IBD and, 47*t*
    - liver disease and, 120*b*
    - malabsorption and, 9*t*
    - pediatric neurologic impairments and, 142
    - after RYGB, 323*t*
    - after SG, 322*t*
    - surgery and, 288
  - iron deficiency anemia, 94*b*
  - irritable bowel syndrome (IBS), 74–85
    - colorectal cancer and, 166
    - diagnosis of, 74–75, 75*f*
    - dietary supplements for, 80–85, 83*t*
    - food allergies/sensitivities and, 75–80
    - marijuana for, 439
    - nutraceutical supplements for, 433
    - peppermint oil for, 82, 83*t*, 439
    - prebiotics and, 260
    - probiotics for, 275–278, 276*b*–277*b*
  - Islam, on EOL, 467*b*–468*b*
  - isoflavones, 152*b*
  - isothiocyanates, 152*b*
  - ivacaftor, 137
- ## J
- Jaboulay stricturoplasty, 300, 301*f*
  - jejunostomy. *See also* gastrojejunostomy
    - for liver disease, 116*b*
    - PEJ, 37
  - Johanson-Blizzard syndrome, 130
  - Judaism, on EOL, 468*b*
  - justice, 453*b*, 456

# K

ketogenic diet, 241*b*, 243  
keystone species, of intestinal microbiome, 225*b*  
Korsakoff syndrome, 199*b*

# L

lactic acidosis, 61  
lactose intolerance  
    IBS and, 76–77  
    with RYGB, 317  
    SBS and, 60  
lactulose, 121  
lansoprazole (Prevacid), 66*b*  
lanugo, 199*b*  
late dumping syndrome, 316  
laxatives. *See also* specific types  
    AN and, 186  
    for colonoscopy, 30  
    drug-nutrient interactions with, 424, 425*b*  
    eating disorders and, 193, 195–196  
LC-MC/MC. *See* liquid-chromatography with tandem mass spectrometry  
LDL-C. *See* low-density lipoprotein-cholesterol  
legal issues  
    of AANH, 452–471, 453*b*–462*b*, 463*f*, 464*b*–470*b*  
    common questions on, 458*b*–459*b*  
    of EOL, 456–457, 456*b*–457*b*  
    with QOL, 452  
legumes, 238*b*, 239–240  
leukopenia, 192*b*, 199*b*  
Levaquin. *See* levofloxacin  
levetiracetam, 142  
levofloxacin (Levaquin), 67*b*  
licorice root (*Glycyrrhiza glabra*), 436  
life-sustaining treatment, 454*b*  
lignans, 152*b*  
lignin, 152*b*  
 $\alpha$ -linoleic acid, 150*b*  
lipase, 192*b*  
lipid-regulating drugs, 429–430, 430*b*  
lipids. *See also* dyslipidemia; hyperlipidemia  
    intestinal microbiome and, 228*b*  
    pancreatitis and, 130  
    in pediatric PN, 386*t*  
    in PN, 367, 368*t*  
    profile, 7  
liquid-chromatography with tandem mass spectrometry (LC-MS/MS), 28*b*  
liraglutide (Saxenda), 181*t*, 329  
lisdexamfetamine, 201  
liver cancer, 149*b*  
    cirrhosis and, 111  
liver disease, 109–123. *See also* cirrhosis; hepatitis

CF and, 135, 137  
clinical presentation and diagnosis of, 110–112, 111*f*, 112*b*  
complications of, 121–123, 122*f*  
eating disorders and, 196–197  
ERCP for, 34  
with HPEN, 414*b*  
intestinal microbiome and, 228*b*  
malnutrition and, 109, 113–121, 115*b*–117*b*, 118*b*–120*b*  
nutraceutical supplements for, 433  
pathogenesis of, 109–110  
tests for, 28*b*  
liver transplantation  
    for CF, 137  
    for cirrhosis, 113  
Lomotil. *See* diphenoxylate with atropine  
Look AHEAD, 179  
loperamide (Imodium)  
    drug-nutrient interactions of, 423  
    for SBS, 66*b*  
low-density lipoprotein-cholesterol (LDL-C), 259–260  
low-residue diet, 53*b*  
lumacaftor, 137  
luteinizing hormone, 192*b*  
lycopene, 152*b*  
lysosomal acid lipase, 28*b*

# M

macronutrient-based diet, 177–178  
macronutrients. *See also* carbohydrate; fat; protein  
    after bariatric surgery, 319–320  
    eating disorders and, 192–193  
magnesium. *See also* hypermagnesemia; hypomagnesemia  
    in antacids, 423*b*  
    antidiarrheals and, 423  
    eating disorders and, 195–196  
    gastric surgery and, 295  
    HPEN and, 415*b*  
    liver disease and, 120*b*  
    pediatric neurologic impairments and, 142  
    in PN, 363*t*, 367, 368*t*  
magnesium gluconate, 64*t*  
magnesium lactate, 64*t*  
malabsorption, 7  
    with celiac disease, 101  
    CF and, 135  
    with EN, 352, 355*b*  
    gastric surgery and, 295  
    HPEN and, 410*b*  
    IBD and, 45  
    inborn errors of metabolism and, 140  
    pancreatic cancer and, 165–166  
    PEI and, 130–131  
    push enteroscopy for, 33

with SBS, 59, 60–62  
 Mallory-Weiss tears, 196, 199b  
 malnutrition  
   antineoplastic therapy and, 155–156, 156b–158b  
   body weight and, 10–11  
   from CACS, 154  
   documentation of, 19–22, 20t–21t, 22b, 23b  
   with head and neck cancer, 162  
   IBD and, 44–46  
   liver disease and, 109, 113–121, 115b–117b, 118b–120b  
   PN for, 362  
 Malnutrition Screening Tool (MST), 4, 5b  
   for cancer, 158  
 manganese  
   malabsorption and, 9t  
   in PN, 369t  
 maple syrup urine disease (MSUD), 141  
 marijuana (*Cannabis sativa*), 438–439  
 mastic gum, 444b  
 Maudsley method (family-based therapy), 202  
 mechanical ventilation, 16, 16b  
 meconium, 137  
 Medicaid, 408  
 Medicare, 407–408, 409b  
 Mediterranean diet  
   for CRC, 166–167  
   for IBD, 54b  
   intestinal microbiome and, 241b, 242  
   for obesity, 179  
 megestrol acetate, 155  
 melatonin, 83, 83t, 84–85  
 MELD. *See* Model for End-stage Liver Disease  
 Ménétrier disease, 293b  
 mercaptopurine, 46  
 mesalazine, 46  
 metabolic acidosis, 193  
 metabolic alkalosis, 193, 198b  
 metabolic bone disease of prematurity, 392  
 metabolic syndrome  
   obesity and, 305b  
   prebiotics and, 258b, 259–260  
 Metchnikoff, Élie, 265  
 metoclopramide, 428b, 429  
 metronidazole (Flagyl)  
   for pediatric dysmotility, 144  
   for SBS, 67b  
 microbial metabolites, 229–230, 229f  
 microbiome, 225b. *See also* intestinal microbiome  
 microbiota, 225b  
 micronutrients. *See also* specific examples  
   after AGB, 322t  
   after bariatric surgery, 320–324, 322t, 323t, 325t–326t  
   for cancer, 160  
   after DS, 323t  
   eating disorders and, 192–193  
   in EN, 346

in HPEN, 414b, 416  
 in pediatric PN, 388  
 in PN, 368, 369t  
 after RYGB, 323t  
 after SG, 322t  
 surgery and, 287, 287b–289b  
 Mifflin-St. Jeor equation, 17, 17b  
 migraine, 94b  
 milk thistle (*Silybum marianum*), 436–437  
 mineral oil, 424, 425b  
 mobile health tracking devices, 6  
 Model for End-stage Liver Disease (MELD), 113  
 molybdenum, 9t  
 monoterpenes, 153b  
 mood disorders, 190  
 motility/dysmotility  
   eating disorders and, 195  
   with EN, 352, 355b  
   EoE and, 139  
   HPEN and, 410b  
   in pediatrics, 141, 142, 143–145  
   procedures, 35–36  
   SBS and, 59  
 MST. *See* Malnutrition Screening Tool  
 MSUD. *See* maple syrup urine disease  
 mucolytics, 137  
 mucositis, 157b  
 muscle mass, 22, 22b, 23b  
 mutualistic microorganisms, 225b

## N

NAFLD. *See* nonalcoholic fatty liver disease  
 naltrexone and bupropion (Contrave), 181t, 329  
 NASH. *See* nonalcoholic steatohepatitis  
 nasogastric tube, 144  
 nasogastric tube  
   for CF, 137  
   for liver disease, 115b  
   for pancreatitis, 128b  
 nasointestinal tube, 115b  
 nasojejunal tube, 128  
 National Health and Nutrition Examination Survey (NHANES), 110  
 National Healthcare Decisions Day (NHDD), 455b  
 National Institute of Allergy and Infectious Diseases (NIAID), 209–210  
 National Weight Control Registry, 177  
 nausea and vomiting. *See also* bulimia nervosa  
   cancer and, 158  
   copper and, 9t  
   with EN, 352, 353, 354b  
   with gastric cancer, 165  
   with HPEN, 413b  
   IBD and, 45

- laxatives and, 195
  - liver disease and, 112*b*
  - micronutrients and, 321
  - pancreatitis and, 128*b*
  - SL and, 315
  - upper endoscopy for, 29
  - vitamin A and, 9*t*
  - NCGS. *See* nonceliac gluten sensitivity
  - necrotizing colitis
    - eating disorders and, 196
    - prebiotics and, 257*b*
  - neomycin, 67*b*
  - neurologic impairments, in pediatrics, 141–143
  - neuropeptide Y, 127
  - Nexium. *See* esomeprazole
  - NHANES. *See* National Health and Nutrition Examination Survey
  - NHDD. *See* National Healthcare Decisions Day
  - niacin (vitamin B3)
    - celiac disease and, 102*b*
    - liver disease and, 119*b*
    - pediatric neurologic impairments and, 142
    - in PN, 369*t*
  - NIAID. *See* National Institute of Allergy and Infectious Diseases
  - night eating disorder, 189*b*
  - Nissen fundoplication, 291–292, 292*f*, 293*f*
  - nitrogen balance, 18, 18*b*
  - nonadherence
    - with bariatric surgery, 328*b*
    - to gluten-free diet, 103
    - to *Helicobacter pylori* eradication, 273
    - to HPEN, 419, 419*b*
  - nonalcoholic fatty liver disease (NAFLD), 109–110
    - celiac disease and, 95
    - insulin resistance and hyperglycemia with, 123
    - prebiotics and, 259–260
  - nonalcoholic steatohepatitis (NASH)
    - obesity and, 305*b*
    - tests for, 28*b*
  - nonceliac gluten sensitivity (NCGS), 80
  - non-critically ill patients, 17, 17*b*
  - nonmaleficence, 453*b*, 456
  - nonsteroidal anti-inflammatory drugs, 43*t*
  - NRS-2002. *See* Nutritional Risk Screening 2002
  - nucleotides
    - in EN, 345*b*
    - in EN infant formulas, 383*b*
  - Nudix hydrolase (NUDT15), 28*b*
  - nutraceutical supplements, 433–446. *See also* aloe vera; turmeric
    - Boswellia serrata* as, 437–438
    - for IBD, 442, 443*b*–445*b*
    - licorice root as, 436
    - marijuana as, 438–439
    - milk thistle as, 436–437
    - peppermint oil as, 82, 83*t*, 439
    - polyphenols as, 437
    - in TCM, 434, 435*b*
    - vitamin D as, 440–442
    - zinc as, 442
  - NUTRIC. *See* Nutrition Risk in the Critically Ill
  - Nutrilipid, 406, 406*t*
  - nutritional anemia profile, 7
  - Nutritional Risk Screening 2002 (NRS-2002), 4, 5*b*
    - PN and, 363
  - nutrition focused physical findings, 12, 13*b*–14*b*
  - Nutrition Risk in the Critically Ill (NUTRIC), 4, 5*b*, 363
  - nuts. *See also* peanuts
    - EoE and, 216
    - intestinal microbiome and, 237–238, 238*b*
- ## O
- obesity. *See also* bariatric surgery
    - BED and, 187
    - colorectal cancer and, 166
    - comorbidities of, 305, 305*b*, 307*t*
    - in critically ill patients, 16, 16*b*
    - diets for, 177–179
    - esophageal cancer and, 163
    - gastric cancer and, 164
    - intestinal microbiome and, 230
    - medical treatment for, 174–181
    - nonsurgical therapies for, 329
    - pathogenesis of, 175
    - pharmacotherapy for, 180, 180*b*, 181*t*
    - prebiotics and, 258*b*, 259
    - weight loss for, 175–176
  - obsessive-compulsive disorder, 190
  - obstructive sleep apnea, 305*b*, 307*t*
  - octreotide (Sandostatin), 67*b*, 68
  - OIT. *See* oral immunotherapy
  - oligomenorrhea, 199*b*
  - omega-3 fatty acids. *See also* fish oils
    - for CACS, 155
    - intestinal microbiome and, 230
    - for pancreatitis, 129
  - Omegaven, 406*t*, 407
  - omeprazole (Prilosec)
    - aloe vera and, 434
    - for SBS, 66*b*
  - ONS. *See* oral nutritional supplements
  - opium
    - drug-nutrient interactions of, 423
    - for SBS, 66*b*
  - oral allergy syndrome (pollen-food allergy syndrome), 210
  - oral contraceptive pills, 43*t*
  - oral food challenge, 210*b*, 212
  - oral immunotherapy (OIT), 213
  - oral nutritional supplements (ONS)
    - for cancer, 160
    - for CRC, 167
  - oral rehydration solutions (ORS), 61, 63–65, 64*t*, 65*b*, 65*t*



organosulfur, 153b  
 orlistat (Xenical, Alli)  
   drug-nutrient interactions of, 430, 431b  
   for obesity, 181t  
 ORS. *See* oral rehydration solutions  
 OSFED. *See* other specified feeding or eating disorder  
 osmotic laxatives, 145  
 osteoarthritis, 305b  
 osteopenia, 46  
 osteoporosis  
   celiac disease and, 94b, 95  
   eating disorders and, 192b, 198b  
   IBD and, 46  
   liver disease and, 123  
 other specified feeding or eating disorder (OSFED), 185, 188–189, 189b  
 ovolacto-vegetarian diet, 179  
 oxcarbazepine, 142

## P

palliative care, 454b  
 pancreatic cancer, 148t, 149b, 165–166  
   PEI and, 130  
 pancreatic disease, 126–133  
   CF and, 135  
   ERCP for, 34  
   nutrition and, 126b, 126–130  
   tests for, 29b  
 pancreatic elastase, 29b  
 pancreatic enzyme replacement therapy (PERT)  
   for CF, 136  
   for PEI, 131–132, 131b  
 pancreatic enzymes  
   for CF, 132  
   drug-nutrient interactions with, 426  
   regulation of, 132  
   for SBS, 67b, 68  
 pancreatic exocrine insufficiency (PEI), 126, 130–132  
 pancreaticoduodenectomy (Whipple procedure), 296–298, 299f  
 pancreatitis, 126  
   clinical presentation of, 127–130  
   eating disorders and, 196  
   HPEN and, 410b  
   inborn errors of metabolism and, 140  
   pancreatic cancer and, 165  
   pediatric PN and, 385b  
   PEI and, 130  
 Pancreaze, 426  
 pancrelipase, 67b  
 pantoprazole (Protonix), 66b  
 pantothenic acid (vitamin B5)  
   malabsorption and, 7t  
   in PN, 369t  
 parenteral nutrition (PN). *See also* home parenteral and enteral nutrition  
   for cancer, 161–162  
   complications of, 371, 372b  
   ethics and legal issues of, 455  
   food/nutrition-related history for, 6  
   formulations for, 365–370, 365b, 366b, 366t, 367b, 368t, 369t, 370b, 371b  
   for IBD, 49  
   indications for, 362–363  
   for liver disease, 118  
   for pancreatitis, 128  
   in pediatrics, 384–394, 385b, 386t, 389t, 390b, 391b, 392t, 393b  
   for SBS, 60, 61, 68, 69, 70b, 296  
   supplemental, 363  
   timing of, 363, 363t  
   venous access for, 363, 363b–364b  
 parenteral nutrition-associated cholestasis (PNAC), 388, 389b  
 patch testing, for food allergies, 211b  
 pathogenic microbes, 225b  
 Patient-Generated Subjective Global Assessment (PG-SGA), 158  
 pattern-based diets  
   for intestinal microbiome, 241–244  
   for obesity, 178–179  
 PCR. *See* polymerase chain reaction  
 peanuts  
   EoE and, 139, 216  
   food allergies to, 207, 208  
 Pearson syndrome, 130  
 pediatrics (children), 135–146. *See also specific topics*  
   AAD in, 271  
   CF in, 135–137  
   constipation in, 145  
   dysmotility in, 143–145  
   EN in, 374–384, 375b, 377t, 378b, 380b, 381b, 383b  
   food allergies in, 213  
   inborn errors of metabolism in, 140–141  
   intestinal microbiome in, 227  
   neurologic impairments in, 141–143  
   PN in, 384–394, 385b, 386t, 389t, 390b, 391b, 392t, 393b  
   prebiotics in, 257b, 258–259  
   probiotics in, 271  
 PEG. *See* percutaneous endoscopic gastrostomy  
 PEI. *See* pancreatic exocrine insufficiency  
 PEJ. *See* percutaneous endoscopic jejunostomy  
 pelvic floor, eating disorders and, 196  
 Pepcid. *See* famotidine  
 peppermint oil, 82, 83t, 439  
 percutaneous endoscopic gastrostomy (PEG), 36–37  
   EN timing after, 340  
 percutaneous endoscopic jejunostomy (PEJ), 37  
 peritonitis  
   eating disorders and, 196  
   EN and, 333  
 personality disorders, 190  
 PERT. *See* pancreatic enzyme replacement therapy



- Pertzye, 426
- PG-SGA. *See* Patient-Generated Subjective Global Assessment
- phenobarbital, 142
- phenolic acid, 153*b*
- phentermine HCl, 181*t*, 329
- phenytoin, 142
- phosphate
  - in antacids, 423*b*
  - in EN infant formulas, 382
- phosphorus
  - celiac disease and, 102*b*
  - gastric surgery and, 295
  - HPEN and, 415*b*
  - liver disease and, 120*b*
  - PN and, 363*t*, 367, 368*t*
  - for SBS, 64*t*
- PN. *See* parenteral nutrition
- PNAC. *See* parenteral nutrition-associated cholestasis
- PN-associated liver disease (PNALD), 68
- pneumothorax, 372*b*
- policy development and review, 453*b*
- pollen-food allergy syndrome (oral allergy syndrome), 210
- POLST. *See* portable medical orders
- polyacetylene, 153*b*
- polycystic ovary syndrome, 305*b*
- polyethylene glycol
  - for AN, 195
  - for CF, 137
  - for colonoscopy, 30
  - for constipation, 137, 145, 195
- polymerase chain reaction (PCR), 28*b*
- polyphenolic acids, 151*b*
- polyphenols, 437
- polyunsaturated fatty acids (PUFAs)
  - in fish oils, 440
  - IBD and, 43
  - intestinal microbiome and, 230, 245*b*
- portable medical orders (POLST), 455*b*, 459*b*
- portal hypertension
  - CF and, 137
  - cirrhosis and, 111
- potassium. *See also* hypokalemia
  - antidiarrheals and, 423
  - eating disorders and, 195
  - HPEN and, 415*b*
  - IBD and, 47*t*
  - in PN, 363*t*, 367, 368*t*
- potassium chloride, 64*t*
- PPIs. *See* proton pump inhibitors
- prealbumin, 18
- prebiotics, 233–234, 254–260
  - benefits of, 257–260, 257*b*–258*b*
  - in diet, 256–257
  - in EN infant formulas, 383*b*
  - vs. fiber, 255–256, 255*f*
  - for hepatic encephalopathy, 122
  - for IBS, 81–82
- polyphenols as, 437
- recommended intake of, 260
- PREDIMED. *See* Prevención con Dieta Mediterránea
- pregnancy
  - after bariatric surgery, 328–329
  - celiac disease and, 96
- Prevacid. *See* lansoprazole
- Prevención con Dieta Mediterránea (PREDIMED), 179
- preventive ethics, 454*b*
- Prilosec. *See* omeprazole
- probiotics, 233–234, 265–279
  - benefits of, 268–269, 269*f*
  - for CDI, 271–272
  - for Crohn's disease, 267, 273–274
  - for diarrhea, 270–273
  - efficacy of, 267–268
  - in EN, 345*b*
  - in EN infant formulas, 383*b*
  - for *Helicobacter pylori*, 273
  - for hepatic encephalopathy, 122
  - for IBD, 273–275
  - for IBS, 81–82, 275–278, 276*b*–277*b*
  - nomenclature for, 268*b*
  - for pancreatitis, 129
  - safety of, 278–279
  - taxonomy of, 267, 267*b*
  - for ulcerative colitis, 267, 274–275
- prochlorperazine, 426*b*
- prokinetic agents
  - drug-nutrient interactions of, 428–429, 428*b*
  - peppermint oil as, 439
- protectants, 426–428, 427*b*
- protein
  - after bariatric surgery, 319
  - for cancer, 159–160
  - in EN, 341*b*–345*b*, 346
  - in EN infant formulas, 380–381, 380*b*
  - intestinal microbiome and, 245*b*
  - liver disease and, 118*b*
  - nitrogen balance and, 18, 18*b*
  - obesity diet and, 177–178
  - pancreas and, 126
  - pancreatitis and, 129*b*, 130
  - for pediatric dysmotility, 144
  - in pediatric PN, 387
  - profile, 7
  - refeeding syndrome and, 201
  - requirements for, 17–18
  - surgery and, 286
- prothrombin time (PT), 415*b*
- Protonix. *See* pantoprazole
- proton pump inhibitors (PPIs)
  - for AAD, 270
  - drug-nutrient interactions of, 426–428, 427*b*

peppermint oil and, 439  
for SBS, 66b  
prucalopride, 144  
psoriasis, 94b  
psoriatic arthritis, 230  
PT. *See* prothrombin time  
PUFAs. *See* polyunsaturated fatty acids  
purging disorder, 189b  
push enteroscopy, 33  
pyridostigmine, 144  
pyridoxine (vitamin B6)  
celiac disease and, 101  
liver disease and, 120b  
malabsorption and, 8t  
in PN, 369t

## Q

QFT4. *See* QuantiFeron-TB Gold Plus  
Qing-Dai. *See* Indigo naturalis  
quality of life (QOL), 3b  
with cancer, 167  
with celiac disease, 99  
ethics and legal issues with, 452  
with HPEN, 418, 418b  
with IBD, 46  
with IBS, 74  
with PN, 70b  
QuantiFeron-TB Gold Plus (QFT4), 28b  
Quinlan, Karen Ann, 456b

## R

rabeprazole (AcipHex), 66b  
radiation-induced diarrhea, 272–273  
radiation therapy  
malnutrition from, 156b  
PEG with, 36  
ranitidine (Zantac)  
aloe vera and, 434  
for SBS, 66b  
rectal abscess, 30  
rectal prolapse  
CF and, 137  
eating disorders and, 196  
pediatric constipation and, 145  
red meat  
alpha-gal syndrome and, 209  
cancer and, 149t  
IBD and, 43  
pancreatic cancer and, 165  
refeeding syndrome, 201  
with EN, 357b  
with HPEN, 410–411, 413b, 414b

with pediatric PN, 392–393, 393b  
with PN, 372b  
refined sugar, 43  
religion, on EOL, 465, 467b–468b  
resting metabolic rate (RMR)  
in critically ill patients, 16, 16b  
in non-critically ill patients, 17, 17b  
retinol, 153b  
retinol-binding protein, 18  
riboflavin (vitamin B2)  
malabsorption and, 7t  
in PN, 369t  
prochlorperazine and, 426b  
richness, of intestinal microbiome, 225b  
rifaximin (Xifaxan)  
for hepatic encephalopathy, 121  
for pediatric dysmotility, 144  
for SBS, 67b  
RMR. *See* resting metabolic rate  
Roux-en-Y gastric bypass (RYGB), 306, 308, 309, 310f  
management of, 315–318  
micronutrients after, 323t

## S

S-adenosyl-L-methionine (SAdMe), 121  
saline laxatives, 424, 425b  
SAdMe. *See* S-adenosyl-L-methionine  
Sandostatin. *See* octreotide  
saponins, 152b  
Saxenda. *See* liraglutide  
SBS. *See* short-bowel syndrome  
SCCM. *See* Society of Critical Care Medicine  
SCD. *See* specific carbohydrate diet  
SCFAs. *See* short-chain fatty acids  
Schiavo, Theresa Marie (Terri), 457b  
Scientific Association for Probiotics and Prebiotics, 265  
scombroid poisoning, 209–210  
SDMs. *See* surrogate decision makers  
secretin, 126, 127  
sedentary lifestyle  
colorectal cancer and, 166  
esophageal cancer and, 163  
selective serotonin reuptake inhibitors, 201  
selenium  
cancer prevention from, 153b  
in EN, 345b  
liver disease and, 120b  
malabsorption and, 9t  
pediatric neurologic impairments and, 142  
in PN, 369t  
for SBS, 64t  
surgery and, 288  
senna, 145  
sepsis

- cirrhosis and, 111
  - with HPEN, 412*b*
  - pancreatitis and, 128
- sequential organ failure assessment (SOFA), 4, 5*b*
- serotonin-norepinephrine reuptake inhibitors, 144–145
- SG. *See* sleeve gastrectomy
- SGA. *See* subjective global assessment
- shared decision-making, 454*b*
- shellfish
  - EoE and, 216
  - food allergies to, 207
- short-bowel syndrome (SBS), 59–72
  - classification of, 60–61
  - diets for, 62, 63*t*
  - EN and, 332
  - fluid management for, 63–65, 64*t*, 65*b*, 65*t*
  - HPEN and, 410*b*
  - medications for, 66–69, 66*b*–67*b*
  - nutrition assessment for, 62
  - pathogenesis of, 59–62, 60*b*
  - PN for, 296
  - small bowel transplantation for, 70–71
  - surgery for, 300–303, 301*f*–303*f*, 302*b*
  - surgical reconstruction for, 70, 71*b*
  - treatment and management of, 62–71
- short-chain fatty acids (SCFAs)
  - in EN, 345*b*
  - intestinal microbiome and, 228*b*, 229*f*, 230, 231–232
  - probiotics and, 268
- Shwachman-Diamond syndrome, 130
- SIBO. *See* small intestinal bacterial overgrowth
- Silybum marianum* (milk thistle), 436–437
- single-balloon enteroscopy, 34
- Sjögren syndrome, 94*b*
- skin prick testing (SPT), for food allergies, 210, 211*b*, 212
- sleeve gastrectomy (SG), 306, 308, 309, 310*f*
  - management of, 314–315
  - micronutrients after, 322*t*
- SMA. *See* superior mesenteric artery syndrome
- small intestinal bacterial overgrowth (SIBO)
  - pediatric dysmotility and, 144
  - SBS and, 61, 62
- small intestine (bowel). *See also* intestinal microbiome; short-bowel syndrome
  - cancer, 148*t*, 165
  - polyps, 31
  - surgery, 296, 298*b*
- SMART goals, for obesity, 176
- SmartPill capsule, 32
- SMOFlipid, 406–407, 406*t*
- smoking
  - cancer and, 149*t*
  - colorectal cancer and, 166
  - esophageal cancer and, 163
  - gastric cancer and, 164
  - IBD and, 43*t*
  - osteoporosis and, 123
  - pancreatic cancer and, 165
- Society of Critical Care Medicine (SCCM)
  - on critically ill patients, 16–17
  - on nutrition screening, 4
  - on protein requirements, 18
- sodium. *See also* hypernatremia; hyponatremia
  - antidiarrheals and, 423
  - liver disease and, 119*b*
  - in PN, 363*t*, 367, 368*t*
  - SBS and, 61, 64
- sodium chloride, 136
- SOFA. *See* sequential organ failure assessment
- somatostatin, 67*b*, 126
- soy
  - for CF, 138
  - in EN infant formulas, 380–381
  - EoE and, 139, 216
  - pediatric PN and, 385*b*
  - specific carbohydrate diet (SCD), 50*b*
- SPT. *See* skin prick testing
- starvation, eating disorders and, 195, 198*b*, 199*b*
- steatorrhea
  - CF and, 136
  - PEI and, 130–131
- stenosis, 37
- stimulant laxatives
  - aloe vera as, 84
  - for constipation, 145
  - drug-nutrient interactions with, 424, 425*b*
- stomatitis, 157*b*
- strictureplasty, 300, 300*f*
- STW 5 (Iberogast), 82–83, 83*t*
- subjective global assessment (SGA), 18–19, 19*f*
  - for cancer, 158
  - for liver disease, 112*b*
  - for pediatric neurologic impairments, 142
- substance use disorders, 190
- subtotal gastrectomy with vagotomy, 295*b*
- sucrose, 77–78
- sulfasalazine
  - drug-nutrient interactions of, 429, 429*b*
  - IBD and, 45, 46
- superior mesenteric artery (SMA) syndrome, 196
- surgery. *See also* bariatric surgery
  - energy and, 285, 285*t*
  - EN timing after, 340
  - esophagectomy, 291–292, 291*f*, 292*b*, 292*f*, 293*b*
  - fluid balance and, 286
  - gastric, 293–295, 294*f*, 295*b*–297*b*
  - for gastrointestinal disorders, 284–303, 290*f*
  - for head and neck cancer, 289
  - ileostomy and colostomy, 298, 299*b*
  - micronutrients and, 287, 287*b*–289*b*
  - pancreaticoduodenectomy, 296–298, 299*f*
  - protein and, 286

for SBS, 300–303, 301*f*–303*f*, 302*b*  
small intestine, 296, 298*b*  
surrogate committee, 454*b*  
surrogate decision makers (SDMs), 453*b*, 454*b*, 465*b*  
synbiotics, 233–234

## T

T1DM. *See* type 1 diabetes mellitus  
Tagamet. *See* cimetidine  
targeted cancer therapy, 156*b*  
TCM. *See* traditional Chinese medicine  
teach-back method of education, 454*b*  
teduglutide (GATTEX)  
    drug-nutrient interactions of, 430–431, 431*b*  
    for SBS, 69  
testosterone, 192*b*  
tetracycline  
    pancreatitis and, 127  
    for SBS, 67*b*  
tezacaftor, 137  
thiamin (vitamin B1)  
    after AGB, 322*t*  
    after bariatric surgery, 325*t*  
    after BPD/DW, 323*t*  
    eating disorders and, 194  
    liver disease and, 119*b*  
    malabsorption and, 7*t*  
    in PN, 369*t*  
    refeeding syndrome and, 201  
    after RYGB, 323*t*  
    after SG, 322*t*  
    surgery and, 287  
thiopurine methyltransferase (TPMT), 28*b*  
thrombocytopenia, 192*b*, 199*b*  
thyroid function tests, 192*b*  
time frame of weight loss, 11  
tissue transglutaminase (tTG), 92, 96–97, 96*t*  
TMA. *See* trimethylamine  
TMAO. *See* trimethylamine-*N*-oxide  
TNF- $\alpha$ , 259  
tobramycin, 137  
tocopherol, 153*b*  
topiramate  
    for BED, 201  
    for obesity, 329  
total gastrectomy, 295*b*  
TPMT. *See* thiopurine methyltransferase  
trace elements  
    malabsorption and, 7–9, 7*t*–9*t*  
    in pediatric PN, 388  
    in PN, 368, 369*t*  
traditional Chinese medicine (TCM), 434, 435*b*  
Tralement, 416, 416*t*  
transdisciplinary function, 454*b*

transferrin, 18  
travelers diarrhea, 258*b*  
triage committee, 454*b*  
tricyclic antidepressants  
    drug-nutrient interactions of, 426*b*  
    for pediatric dysmotility, 144–145  
triglycerides. *See also* hypertriglyceridemia  
    HPEN and, 415*b*  
    PN and, 363*t*  
trimethylamine (TMA), 230  
trimethylamine-*N*-oxide (TMAO), 230  
Tripterygium wilfordii, 444*b*  
*Triticum aestivum* (wheat grass), 444*b*  
tTG. *See* tissue transglutaminase  
turmeric (curcumin), 438  
    cancer prevention from, 151*b*  
    for IBS, 83, 83*t*  
Turner syndrome, 94*b*  
24-hour diet recall, 5–6  
type 1 diabetes mellitus (T1DM)  
    celiac disease and, 93, 94*b*, 95–96  
    eating disorders and, 190  
    intestinal microbiome and, 230  
    PEI and, 130  
type 2 diabetes mellitus  
    intestinal microbiome and, 230  
    obesity and, 305*b*, 307*t*  
    prebiotics and, 258*b*

## U

UBW. *See* usual body weight  
UFED. *See* unspecified feeding or eating disorder  
ulcerative colitis  
    aloe vera for, 434  
    Boswellia serrata for, 437  
    clinical presentation of, 44  
    colorectal cancer and, 166  
    marijuana for, 439  
    probiotics for, 267, 274–275  
    turmeric for, 438  
ulcers  
    RYGB and, 317  
    upper endoscopy for, 29  
ultrasound (US), 12  
unspecified feeding or eating disorder (UFED), 185  
upper endoscopy, 29–30  
urinary incontinence, 305*b*  
ursodeoxycholic acid (Actigall)  
    for CF, 137  
    for SBS, 67*b*, 68  
US. *See* ultrasound  
ustekinumab, 28*b*  
usual body weight (UBW), 10

# V

## vaccination

- for hepatitis A, 113
- for hepatitis B, 113
- for influenza, 259
- prebiotics and, 259

## vagotomy, 295*b*

## valproate, 142

## vasopressin, 126

## vedolizumab, 28*b*

## vegan diet

- intestinal microbiome and, 241*b*, 242–243
- for obesity, 179

## vegetables, intestinal microbiome and, 238–239, 238*b*, 245*b*

## vegetarian diet

- intestinal microbiome and, 241*b*, 242–243
- for obesity, 179

## very low-calorie diet (VLCD), 177

## video capsule endoscopy, 98

## Viokace, 426

## visceral transplantation, for SBS, 301–303, 302*b*, 303*f*

## vitamin A

- after AGB, 322*t*
- after bariatric surgery, 326*t*
- after BPD/DW, 323*t*
- celiac disease and, 101
- for CF, 136
- cholestyramine and colestipol and, 429
- IBD and, 47*t*
- liver disease and, 119*b*
- malabsorption and, 8*t*
- pancreatic cancer and, 166
- for PEI, 131
- in PN, 369*t*
- after RYGB, 323*t*
- for SBS, 64*t*
- after SG, 322*t*
- surgery and, 287

## vitamin B1. *See* thiamin

## vitamin B3. *See* niacin

## vitamin B5. *See* pantothenic acid

## vitamin B6. *See* pyridoxine

## vitamin B7. *See* biotin

## vitamin B9. *See* folate

## vitamin B12 (cobalamin)

- after AGB, 322*t*
- after bariatric surgery, 326*t*
- after BPD/DW, 323*t*
- celiac disease and, 93, 101, 102*b*
- eating disorders and, 194
- gastric surgery and, 295, 297*b*
- IBD and, 46–47, 47*t*
- liver disease and, 120*b*
- malabsorption and, 8*t*

## pancreatic cancer and, 166

## pediatric neurologic impairments and, 142

## in PN, 369*t*

## after RYGB, 323*t*

## SBS and, 61, 62

## after SG, 322*t*

## surgery and, 287

## vitamin C (ascorbic acid)

## cancer prevention from, 151*b*

## gastric surgery and, 297*b*

## malabsorption and, 8*t*

## in PN, 369*t*

## surgery and, 287

## vitamin D

## after AGB, 322*t*

## after bariatric surgery, 326*t*

## after BPD/DW, 323*t*

## celiac disease and, 101

## for CF, 136

## cholestyramine and colestipol and, 429

## for CRC, 167

## eating disorders and, 192*b*, 193

## gastric surgery and, 295, 297*b*

## IBD and, 43*t*, 46, 47, 47*t*

## liver disease and, 120*b*

## malabsorption and, 8*t*

## as nutraceutical supplement, 440–442

## for osteoporosis, 123

## pancreatic cancer and, 165, 166

## pediatric neurologic impairments and, 142, 143

## for PEI, 131

## after RYGB, 323*t*

## for SBS, 64*t*

## after SG, 322*t*

## surgery and, 288

## vitamin E

## after AGB, 322*t*

## after bariatric surgery, 326*t*

## after BPD/DW, 323*t*

## cancer prevention from, 153*b*

## celiac disease and, 101

## for CF, 136

## cholestyramine and colestipol and, 429

## IBD and, 47

## liver disease and, 120*b*

## malabsorption and, 8*t*

## pancreatic cancer and, 166

## pediatric neurologic impairments and, 142

## for PEI, 131

## in PN, 369*t*

## after RYGB, 323*t*

## for SBS, 64*t*

## after SG, 322*t*

## surgery and, 288

vitamin K  
after AGB, 322*t*  
after bariatric surgery, 326*t*  
after BPD/DW, 323*t*  
celiac disease and, 101  
for CF, 136  
cholestyramine and colestipol and, 429  
IBD and, 47–48  
liver disease and, 120*b*  
malabsorption and, 8*t*  
pancreatic cancer and, 166  
for PEI, 131  
in PN, 369*t*  
after RYGB, 323*t*  
after SG, 322*t*  
surgery and, 288  
VLCD. *See* very low-calorie diet  
vomiting. *See* nausea and vomiting

## W

waist circumference, 12  
WAO. *See* World Allergy Organization  
water, in EN, 346  
weight-for-length measurement, CF and, 136  
weight gain  
from antineoplastic therapy, 157*b*  
ARFID and, 188*b*  
BN for, 186–187  
for eating disorders, 198, 199–201  
weight loss. *See also* bariatric surgery  
from antineoplastic therapy, 158*b*  
ARFID and, 188*b*  
cancer and, 154–155, 162  
colonoscopy for, 30  
with gastric cancer, 165  
for liver disease, 113  
in malnutrition documentation, 22, 22*b*, 23*b*  
in MST, 5*b*  
in NRS-2002, 5*b*  
for obesity, 175–176  
pancreatic cancer and, 165–166  
PEI and, 130  
pharmacotherapy for, 329  
time frame of, 11  
Wernicke encephalopathy, 199*b*  
Western-style diet  
CRC and, 167  
intestinal microbiome and, 232, 241*b*, 242  
pancreatic cancer and, 165  
wheat  
EoE and, 139, 216  
food allergies to, 207  
IBS and, 80

wheat grass (*Triticum aestivum*), 444*b*  
Whipple procedure (pancreaticoduodenectomy), 296–298, 299*f*  
Wilson disease, 28*b*  
wireless capsule endoscopy, 31–32  
World Allergy Organization (WAO), 209  
wormwood (*Artemisia absinthium*), 444*b*

## X

Xenical. *See* orlistat  
xerostomia, 158*b*  
Xifaxan. *See* rifaximin  
*Xilei-san* (XLS), 445*b*

## Z

Zantac. *See* ranitidine  
Zenpep, 426  
zinc  
after AGB, 322*t*  
after bariatric surgery, 326*t*  
after BPD/DW, 323*t*  
celiac disease and, 101, 102*b*  
CF and, 136  
eating disorders and, 194–195  
for hepatic encephalopathy, 122  
IBD and, 47*t*, 48  
liver disease and, 120*b*  
malabsorption and, 9*t*  
as nutraceutical supplement, 442  
pediatric neurologic impairments and, 142  
in PN, 369*t*  
after RYGB, 323*t*  
after SG, 322*t*  
surgery and, 289  
zinc sulfate, 64*t*  
Zollinger-Ellison syndrome, 130, 293*b*  
zonisamide, 201